

09-27-00

A PATENTS

Rev. 12/99
Modified PTO 1082
For A Small Entity

Attorney Docket No. VPI/SW/002 CIP2 FWC DIV2 CON

Applicants : Paul R. Sleath et al.

For : INTERLEUKIN 1 β PROTEASE AND INTERLEUKIN 1 β PROTEASE INHIBITORSEXPRESS MAIL CERTIFICATION"Express Mail" mailing label number EI186820816USDate of Deposit September 26, 2000

I hereby certify that this transmittal letter and the other papers and fees identified in this transmittal letter as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and are addressed to the Hon. Assistant Commissioner for Patents, Washington, D.C. 20231.

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231


 Claire J. Saintil

TRANSMITTAL LETTER FOR RULE 53(b)
CONTINUING PATENT APPLICATION

Sir:

This is a request for filing a ☒ continuation, ☐ divisional, application of pending prior Application No. 09/039,657, filed March 16, 1998.

Transmitted herewith for filing are the ☒ specification; ☒ claims; ☒ abstract; ☒ declaration; ☐ power of attorney; for the above-identified patent application.

The enclosed declaration is:

- ☐ Newly executed (original or copy).
- ☒ Copy from a prior application (37 C.F.R. § 1.63(d)).
- ☐ A signed statement is attached deleting inventors named in the prior application (37 C.F.R. §§ 1.63(d)(2) and 1.33(b)).
- ☒ The entire disclosure of the prior application, from which a copy of the declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
- ☒ The prior application, Application No. 09/039,657, filed March 16, 1998, is assigned of record to Vertex Pharmaceuticals Incorporated.

☒ Also transmitted herewith are:

6 sheets of:

- ☒ Formal drawings.

EI186820816US

09/26/00
JC929 U.S. PTO

jc929 U.S. PTO
09/26/00

☐ Informal drawings. Formal drawings will be filed during the pendency of this application.

☐ An associate power of attorney.

☐ A certified copy of the priority document, _____ application, No. _____, filed _____.

☒ A verified statement to establish small entity status under 37 C.F.R. §§ 1.9 and 1.27 ☐ is enclosed, ☒ was filed in the prior application and such status is still proper and desired (37 C.F.R. § 1.28(a)).


The filing fee has been calculated as shown below:

FOR	NUMBER FILED		NUMBER EXTRA		RATE		FEE
BASIC FEE							\$ 345.00
TOTAL CLAIMS	49	- 20 =	29	x	\$ 09	=	\$ 261.00
INDEPENDENT CLAIMS	9	- 3 =	6	x	\$ 39	=	\$ 234.00
<input type="checkbox"/> A MULTIPLE DEPENDENT CLAIM				+	\$130	=	\$
TOTAL							\$ 840.00

☒ A check in the amount of \$840.00 in payment of the filing fee is transmitted herewith.

☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16 in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to Deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.

☐ Please charge \$ _____ to Deposit Account No. 06-1075 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.


James F. Haley, Jr. (27,794)
Lisa A. Dixon (40,995)
Attorneys for Applicants
Scott D. Miller (43,803)
Agent for Applicants
Fish & Neave
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000

INVENTOR INFORMATION

Inventor One Given Name:: Paul R
Family Name:: Sleath
Postal Address Line One:: 836 West Armour Street
City:: Seattle
State or Province:: Washington
Country:: USA
Postal or Zip Code:: 98119
City of Residence:: Seattle
State or Province of Residence:: Washington
Country of Residence:: USA
Citizenship Country:: USA
Inventor Two Given Name:: Roy A
Family Name:: Black
Postal Address Line One:: 8062 30th Avenue N.E.
City:: Seattle
State or Province:: Washington
Country:: USA
Postal or Zip Code:: 98115
City of Residence:: Seattle
State or Province of Residence:: Washington
Country of Residence:: USA
Citizenship Country:: USA
Inventor Four Given Name:: Shirley R
Family Name:: Kronheim
Postal Address Line One:: 11526 36th Avenue N.E.
City:: Seattle
State or Province:: Washington
Country:: USA
Postal or Zip Code:: 98125
City of Residence:: Seattle
State or Province of Residence:: Washington
Country of Residence:: USA
Citizenship Country:: USA

CORRESPONDENCE INFORMATION

Correspondence Customer Number:: 1473
Fax One:: 212 596 9090
Electronic Mail One:: ldixon@fishneave.com
Electronic Mail Two:: smiller@fishneave.com

APPLICATION INFORMATION

Title Line One:: INTERLEUKIN 1BETA PRROTEASE AND INTERLEU
Title Line Two:: KIN 1BETA PROTEASE INHIBITORS
Total Drawing Sheets:: 4
Formal Drawings?: Yes

Application Type:: Utility
Docket Number:: VPISW002CON
Secrecy Order in Parent Appl.?:: No

REPRESENTATIVE INFORMATION

Representative Customer Number:: 1473
Registration Number One:: 40995
Registration Number Two:: 43803

CONTINUITY INFORMATION

This application is a:: CONTINUATION OF
> Application One:: 09/039657
Filing Date:: 03-16-1998

Which is a:: DIVISION OF
>> Application Two:: 08/440179
Filing Date:: 05-12-1995
Patent Number:: 5756465

Which is a:: DIVISION OF
>>> Application Three:: 08/203716
Filing Date:: 02-28-1994

Which is a:: CONTINUATION OF
>>>> Application Four:: 07/750644
Filing Date:: 08-30-1991
Patent Number:: 5416013

Which is a:: CONTINUATION IN PART OF
>>>>> Application Five:: 07/656759
Filing Date:: 02-13-1991

Which is a:: CONTINUATION IN PART OF
>>>>>> Application Six:: 07/505298
Filing Date:: 04-04-1990

Source:: PrintEFS Version 1.0.1

- 1 -

TITLE**INTERLEUKIN 1 β PROTEASE
AND INTERLEUKIN 1 β PROTEASE INHIBITORS**

5

TECHNICAL FIELD OF THE INVENTION

This invention relates to an interleukin 1 β protease enzyme (IL-1 β pro) having biological activity to cleave inactive precursor interleukin-1 β (IL-1 β) polypeptides into active mature IL-1 β polypeptides. More specifically, the invention provides an isolated IL-1 β pro polypeptide and derivatives thereof that are capable of cleaving a particular amino acid sequence, including the amino acid sequence at the N-terminus of human IL-1 β . The present invention further provides a group of compounds that can inhibit IL-1 β pro activity and thereby function as IL-1 antagonists.

20

BACKGROUND OF THE INVENTION

Interleukin 1 β (IL-1 β) is a 17.5 kDa polypeptide hormone synthesized and secreted by stimulated monocytes. The initial translation product of IL-1 β is a larger 31 kDa biologically inactive precursor polypeptide. The N-terminus of biologically active, mature IL-1 β derived from human activated monocytes has been characterized by an N-terminal amino acid sequence beginning with Ala-Pro. See, for example, European Patent Application EP-A 0165654 and March et al., Nature (London) 315:641-47 (1985) for sequence information of human IL-1 β .

25

Many physiological actions and biological activities of IL-1 have been identified. IL-1 biological activity is often determined by assaying for stimulation of thymocyte proliferation or by measuring interleukin-2 (IL-2) biological activity. IL-1

30

35

activities include stimulation of B-lymphocyte maturation, lymphocyte proliferation, stimulation of fibroblast growth and induction of acute-phase protein synthesis by hepatocytes.

5 Other biological activities have been attributed to IL-1 polypeptides. These include control of differentiation and activation of lymphocytes, stimulation of lymphokine and prostaglandin production, promotion of inflammation, induction of acute phase
10 proteins, stimulation of bone resorption, and alteration of the level of iron and zinc in blood. Moreover, it has recently been found that IL-1 can stimulate the hypothalamus-pituitary-adrenal axis, suggesting that IL-1 is integrated in the complex neuroendocrine network
15 that controls homeostasis. This is further supported by the finding that administration of low doses of IL-I to normal mice results in both a several-fold elevation of glucocorticoid output and in a long-lasting blood glucose concentration increase.

20 The N-terminal Ala residue of human mature IL-1 β is in the 117 position and an Asp residue is in the 116 position counting from the N-terminus of human precursor IL-1 β polypeptide. Mature IL-1 β consists of the C-terminal 153 residues of the precursor
25 polypeptide.

 Maturation and release of mature IL-1 β from macrophages does not proceed by conventional means normally associated with most secretory proteins because the precursor IL-1 β polypeptide lacks a hydrophobic
30 signal sequence. Further, IL-1 β is not associated with a membrane-bound compartment in monocytes. [Singer et al., J. Exp. Med. 167:389-407 (1988)]. Most secretory proteins are characterized by the presence of a hydrophobic stretch of amino acids called a signal
35 sequence. The signal sequence directs the translocation

of the protein across the membrane of the endoplasmic reticulum during protein synthesis. The protein is subsequently ushered out of the cell via exocytosis. Most secreted proteins have a signal sequence at the amino terminal that is removed upon translocation. Other proteins, such as ovalbumin, have an internal signal sequence that is not removed upon translocation. Both precursor forms of IL-1 α and IL-1 β (March et al.) lack any region (either amino terminal or internal) with sufficient hydrophobicity and length to qualify as a signal sequence.

A further indication of an unusual maturation pathway for IL-1 β is the absence of a pair of basic amino acids near the N-terminus of the mature polypeptide. The amino acid sequence Tyr-Val-His-Asp precedes the N-terminal Ala-Pro of the mature human IL-1 β polypeptide. Moreover, Young et al., J. Cell Bio., 107:447-56 (1988) found that fibroblasts transfected with cDNA coding for precursor IL-1 β were unable to process the precursor polypeptide into mature IL-1 β . Instead, the transfected fibroblasts produced high levels of inactive precursor polypeptide. The results reported by Young et al. are consistent with other reports for other cell types, including T cells, epidermal cells and B cells.

Hazuda et al., J. Biol. Chem., 263:8473-79 (1988) have reported that both the precursor and mature forms of IL-1 β appear in the supernatants of activated monocytes with little or no preference. Hazuda et al. suggest that IL-1 β processing is "intimately coordinated" with secretion.

There have been several attempts to characterize or isolate the system responsible for processing IL-1 β from its translated precursor form to its active mature form. Black et al., J. Biol. Chem.,

263:9437-42 (1988) [Black et al. I] suggest that the cleavage pattern of precursor IL-1 β is affected by myeloid cell membranes and results from the action of a plurality of proteases which act as an IL-1 β processing system. A subsequent article by Black et al., J. Biol. Chem., 264:5323-26 (1989) [Black et al. II] describes a single protease that cleaves IL-1 β between His¹¹⁵ and Asp¹¹⁶, one residue upstream from the N-terminal Ala¹¹⁷ of mature IL-1 β . Thus, the protease described in Black et al. II generates a form of IL-1 β one amino acid longer than the mature IL-1 β purified from monocyte cultures. Black et al. II suggests that there may be an aminopeptidase in human blood that removes the N-terminal aspartate residue to complete the processing.

Kostura et al., Proc. Nat Acad Sci. USA, 86:5227-31 (1989) refers to a protease with a similar cleavage pattern but "qualitatively different" from the protease described in Black et al. II. The Kostura et al. protease is characterized as being located in cytosol of monocytic cells. However, Kostura et al. did not further define or isolate the responsible polypeptide.

Finally, Black et al., FEBS Lett., 247:386-90 (1989) [Black et al. III] refer to a protease that generates mature IL-1 β from the precursor polypeptide and is characterized by being inhibited by iodoacetate and N-ethylmaleimide. Black et al. III attempted to purify their protease approximately 500 fold by a process starting by freeze-thawing cell lysates from THP-1 cells (ATTC) four times. Black et al. III centrifuged the lysates for 20 minutes at 36,590 X g. The supernatant was applied to a DEAE-Sephacel column equilibrated with 10 mM Tris-HCl (pH 8.1) and 5 mM dithiothreitol. The protease was eluted with 80-140 mM NaCl. The eluted material was diluted 1:5 with a buffer

of 10 mM Tris-HCl (pH 8.1) and 5 mM dithiothreitol and applied to a procion red agarose column. The protease was eluted with 0.5-0.8 M NaCl, concentrated 20-fold in a Centriprep-10 concentrator, and then subjected to get
5 filtration with Sephadex G-75. This procedure described in Black et al. III failed to demonstrate whether the protease activity was due to a single polypeptide or a group of processing enzymes.

Therefore, there is a need in the art to
10 obtain the isolated system or single protease polypeptide responsible for processing precursor IL-1 β into its mature and biologically active form. The protease functions as an IL-1 agonist to increase IL-1 biological activity in vivo. Moreover, the isolated
15 protease is useful for improving wound healing, treating arthritis, and treating or preventing the onset of autoimmune diseases, such as insulin dependent diabetes melitus, lupus disorders, Graves' disease, Hashimotos disease, and the detrimental side effects of radiation
20 treatment.


Further, isolation and characterization of the protease responsible for processing precursor IL-1 β into its biologically active form aids in designing inhibitors for IL-1 β processing, because the
25 availability of large quantities of IL-1 β pro serves as a useful screening vehicle for finding compounds having IL-1 antagonist activity. Such IL-1 antagonists or IL-1 β pro inhibitors are useful for treating inflammation and transplantation rejection.

A number of protease inhibitors specific for
30 other protease activities have been described and reported in the literature. See, e.g., U.S. Patent Nos. 4,644,055, 4,636,492 and 4,652,552. None of these previously reported protease inhibitors are specific for
35 interleukin 1 β protease activity. None of the

previously described protease inhibitors are effective in inhibiting the activity of interleukin 1 β protease. Therefore, there is a need for a specific IL-1 β pro inhibitor that can prevent the cleavage of preIL-1 β into biologically active IL-1 β . Such an inhibitor can function as an IL-I antagonist. This invention provides IL-I antagonists that prevent the formation of biologically active IL-1 β .

SUMMARY OF THE INVENTION

The present invention is directed to an isolated polypeptide having proteolytic activity for a specific protease cleavage site, wherein the protease activity is specific for a substrate peptide having an amino acid sequence comprising:



wherein R_1 and R_3 are independently any D or L isomer amino acid, R_2 is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R_2 .

Preferably, the substrate peptide is at least eight amino acids in length. The isolated polypeptide is called the interleukin 1 β protease (IL-1 β pro) because it cleaves precursor IL-1 β polypeptide to yield mature IL-1 β polypeptide at a cleavage site between the Asp 116 and Ala 117 residues. This region of precursor IL-1 β corresponds to a species within the genus of protease cleavage sites described herein.

IL-1 β pro is further characterized by a cDNA (Seq. I.D. No. 1) and amino acid sequence (Seq. I.D. No. 2) in Figure 1. Full length (precursor) IL-1 β pro comprises 404 amino acids. Purified IL-1 β pro begins with the Asn-Pro-Ala-Met-Pro sequence beginning with amino acid 120. Based upon a molecular weight analysis, the approximate C-terminus of mature IL-1 β pro is about amino acid 297. However, molecular weight determination


indicates that the C-terminus of the mature IL-1 β pro enzyme is from about amino acid 278 to about amino acid 315. The present invention comprises an isolated IL-1 β pro polypeptide or a derivative, analog, or allelic variant thereof displaying biological activity to proteolytically cleave human precursor IL-1 β polypeptide at a cleavage site between the Asp 116 and Ala 117 residues.

Figure 1 also shows a nucleotide sequence encoding a 404 amino acid polypeptide having IL-1 β pro biological activity. The present invention further comprises an isolated DNA sequence encoding IL-1 β pro or a derivative, analog or allelic variant thereof displaying biological activity to proteolytically cleave human precursor IL-1 β polypeptide at a cleavage site between the Asp 116 and Ala 117 residues. The isolated DNA sequence is selected from the group consisting of the nucleotide sequences in Figure 1 beginning at nucleotide 1 and extending to nucleotide 1232, beginning at nucleotide 374 and extending to nucleotide 1232, beginning at nucleotide 374 and extending to a nucleotide from about 851 to about 962, DNA sequences which detectably hybridize to the Figure 1 sequence from nucleotide 1 to nucleotide 1232 and encode a polypeptide displaying biological activity to proteolytically cleave human precursor IL-1 β polypeptide at a cleavage site between the Asp 116 and Ala 117 residues, and DNA sequences which, due to degeneracy of the genetic code, encode a mammalian IL-1 β pro polypeptide encoded by any of the foregoing DNA inserts and sequences.

The present invention further comprises a recombinant expression vector comprising an isolated DNA sequence as described herein and a host cell which comprises the recombinant expression vector.

The present invention also provides substituted peptide inhibitor compounds comprising an amino acid sequence of from 1 to about 5 amino acids, having an N-terminal protecting group and a C-terminal Asp residue connected to an electronegative leaving group. Preferably, the amino acid sequence corresponds to at least a portion of the amino acid sequence Ala-Tyr-Val-His-Asp.

The inhibitor compounds of the present invention have the formula:



Where Z is an N-terminal protecting group; Q_2 is 0 to 4 amino acids such that the sequence Q_2 -Asp corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of sequence listing I.D. No. 3; and Q_1 comprises an electronegative leaving group. Z is preferably C_1 - C_6 alkylketone, benzyl, acetyl, alkoxy carbonyl, benzloxy carbonyl or C_1 - C_6 alkyl carbonyl. More preferably, Z is t-butoxy carbonyl (t-Boc), acetyl carbonyl or benzyloxy carbonyl (Cbz).

Q_1 is preferably C_1 - C_3 alkyl, an aldehyde diazomethyl ketone or halomethyl ketone. More preferably, Q_1 is an aldehyde or fluoromethyl ketone.

The present invention further provides reversible and irreversible IL-1 β pro inhibitors. Irreversible inhibitors are inhibitor compounds comprising an amino acid sequence of from 1 to about 5 amino acids having an N-terminal protecting group and a C-terminal Asp residue connected to a diazomethyl ketone or a halomethyl ketone, wherein the amino acid sequence corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3.

Reversible IL-1 β inhibitors are compounds comprising an amino acid sequence of from 1 to about 5 amino acids having an N-terminal protecting group and a

C-terminal Asp residue connected to an aldehyde moiety, wherein the amino acid sequence corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3.

5 The present invention also provides a method of inhibiting the physiological actions of interleukin 1 β in a mammal in need of such treatment, comprising administering to said mammal an effective amount of a compound of the formula:



where Z is an N-terminal protecting group; Q₂ is 0 to 4 amino acids such that the sequence Q₂-Asp corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3; and Q₁ comprises
15 an electronegative leaving group.

In a preferred embodiment, Q₁ is a fluoromethyl ketone and inhibition is irreversible. In another preferred embodiment, Q₁ is an aldehyde moiety and inhibition is reversible.

20 The present invention still further provides a pharmaceutical composition comprising a physiologically acceptable carrier and a compound comprising an amino acid sequence of from 1 to about 5 amino acids having an N-terminal protecting group and a C-terminal Asp residue
25 connected to an electronegative leaving group, wherein said amino acid sequence corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3.

30 The present invention still further provides a method of treating inflammation associated with autoimmune disease in a mammal in need of such treatment comprising administering to said mammal an effective anti-inflammatory amount of a compound comprising an amino acid sequence of from 1 to about 5 amino acids
35 having an N-terminal protecting groups and a C-terminal

Asp residue connected to an electronegative leaving group, wherein said amino acid sequence corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3.

5 The present invention further comprises a method for treating arthritis, a method for treating an autoimmune disease in a susceptible individual, a method for improving wound healing, and a method for reducing the detrimental side effects of radiation treatment.

10 All of the methods comprise administering a therapeutically effective amount of an isolated IL-1 β protease or a biologically active derivative thereof in a suitable pharmaceutical carrier.

15 BRIEF DESCRIPTION OF THE DRAWINGS

 In the drawings forming a portion of this disclosure:

 Figure 1 shows the DNA (Seq. I.D. No. 1) and corresponding amino acid sequence (Seq. I.D. No. 2) for a polypeptide having IL-1 β pro biological activity and corresponding to human mature IL-1 β pro or a biologically active fragment thereof.

 Figure 2 is the amino acid sequence of preIL-1 β (Seq. I.D. No. 3), as published by March et al., Nature (London), 315(6021):641-647 (1985). The amino acid residues are numbered (underneath the sequence) beginning with the initiator methionine.

 Figure 3 shows a Western Blot analysis of products generated by IL-1 β pro in the presence and absence of the IL-1 β pro inhibitor Boc-Asp-CH₂F. Products were subjected to SDS-PAGE, transferred to nitrocellulose, and probed with an antibody raised against the COOH terminus of mature IL-1 β . Lane 3, preIL-1 β incubated with 25 μ M of inhibitor; lane 4, preIL-1 β incubated with 10 μ M of inhibitor; lane 5,

preIL-1 β incubated with 5 μ M inhibitor, lane 6, preIL-1 β incubated with 1 μ M inhibitor.

DETAILED DESCRIPTION OF THE INVENTION

5

I. Interleukin 1 β Protease


Utilizing polymerase chain reaction (PCR) procedures and other techniques, we have isolated, purified, characterized, and expressed a mammalian IL-1 β pro polypeptide and active fragments thereof.

10

The availability of abundant quantities of a recombinant IL-1 β pro enzyme has further allowed us to find inhibitor compounds capable of inhibiting IL-1 β pro activity and thereby function as IL-1 antagonists. Further, use of IL-1 β pro has IL-1 agonist activity.

15

Thus, the invention relates to mammalian IL-1 β pro polypeptides, derivatives, analogs and allelic variants thereof having proteolytic activity for a substrate peptide having an amino acid sequence comprising:



20

wherein R_1 and R_3 are independently any D or L isomer amino acid, R_2 is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R_2 .

Preferably, the substrate peptide is at least eight amino acids in length. Most preferably, R_2 is Gly.

25

Mammalian IL-1 β pro is preferably a human IL-1 β pro and has substrate specificity for a substrate peptide having the amino acid sequence described herein. Preferably, the human IL-1 β pro polypeptide or derivative thereof is a polypeptide having biological activity that cleaves human precursor IL-1 β polypeptide to yield human mature IL-1 β polypeptide.

30

IL-1 β pro is further characterized by the cDNA (Seq. I.D. No. 1) and amino acid sequence (Seq. I.D. No. 2) in Figure 1. Full length (precursor) IL-1 β pro comprises 404 amino acids. Purified IL-1 β pro begins

35

with the Asn-Pro-Ala-Met-Pro sequence beginning with amino acid 120. Based upon a molecular weight analysis, the approximate C-terminus of mature IL-1 β pro is about amino acid 297. However, the molecular weight
5 determination indicates that the C-terminus of the mature enzyme is from about amino acid 278 to about amino acid 315. The present invention comprises an isolated IL-1 β pro polypeptide or a derivative, analog, or allelic variant thereof displaying biological
10 activity to proteolytically cleave a human precursor IL-1 β polypeptide at a cleavage site between the Asp 116 and Ala 117 residues. For the purposes of this application, the term "IL-1 β pro" shall encompass the amino acid sequence shown in Figure 1, plus all allelic
15 variants, derivatives, analogs and fragments of this sequence that display IL-1 β pro biological activity.

IL-1 β pro biological activity is determined, for example, by assaying for IL-1 activity with a precursor IL-1 β polypeptide. Precursor IL-1 β is
20 inactive, while mature IL-1 β is an active IL-1 polypeptide. A method for measuring IL-1 β pro activity is described in Black et al. II. Briefly, this method provides approximately five microliters of precursor IL-1 β (pre IL-1 β) (10-50 μ g/ml prepared as described in
25 Black et al. I) incubated with 10 μ l of IL-1 β pro polypeptide or another substance suspected of having IL-1 β pro biological activity. The incubation proceeds for approximately one hour at approximately 37°C and is terminated by the addition of 15 μ l of 2 X SDS sample
30 buffer followed by boiling for five minutes. The boiled sample is electrophoresed on a SDS-polyacrylamide gel and placed onto a Western blot using an IL-1 β C-terminal-specific monoclonal antibody, such as 16F5 described in Black et al. I.

Figure 1 also shows a nucleotide sequence encoding a 404 amino acid sequence having IL-1 β pro biological activity. The present invention further comprises an isolated DNA sequence encoding IL-1 β pro or a derivative, analog or allelic variant thereof displaying biological activity to proteolytically cleave a human precursor IL-1 β polypeptide at a cleavage site between the Asp 116 and Ala 117 residues. The isolated DNA sequence is selected from the group consisting of the nucleotide sequences in Figure 1 beginning at nucleotide 1 and extending to nucleotide 1232, beginning at nucleotide 374 and extending to nucleotide 1232, beginning at nucleotide 374 and extending to a nucleotide from about 851 to about 962, DNA sequences which detectably hybridize to the Figure 1 sequence from nucleotide 1 to nucleotide 1232 and encode a polypeptide displaying biological activity to proteolytically cleave a human precursor IL-1 β polypeptide at a cleavage site between the Asp 116 and Ala 117 residues, and DNA sequences which, due to degeneracy of the genetic code, encode a mammalian IL-1 β pro polypeptide encoded by any of the foregoing DNA inserts and sequences.

Inventive DNA sequences that detectably hybridize to the Figure 1 nucleotide sequence from nucleotide 1 to nucleotide 856, hybridize under conditions of high or severe stringency. Severe or high stringency conditions comprise, for example, overnight hybridization at about 68°C in a 6 X SSC solution followed by washing at about 68°C in a 0.6 X SSC solution.

Antisense oligonucleotides can be synthesized (by conventional phosphodiester techniques such as by Synthecell, Rockville, MD) that are complementary to unique regions of at least 18 bases at the initiation codon (TACCGGCTGTTCCAGGAC, Seq. I.D. No. 4) or

(TACCTATTCTGGGCTCGA, Seq. I.D. No. 5) complementary to bases 18-36 and 168 to 196, respectively in Figure 1, at the N-terminus of mature IL-1 β pro (TTGGTCGATACGGGTGT, Seq. I.D. No. 6) complementary to bases 374 to 392 in Figure 1, at the approximate C terminus after protease cleavage (CACCACACCAAATTTCTA, Seq. I.D. No. 7) complementary to bases 890 to 908 in Figure 1, or at a region immediately 5' to the termination codon (ATGGAGAAGGGTCCTGTA, Seq. I.D. No. 8) complementary to bases 1205 to 1229 in Figure 1.

The primary amino acid structure of IL-1 β pro or its active fragment thereof may be modified by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like, or by creating amino acid sequence mutants or derivatives. Covalent derivatives of IL-1 β pro are prepared by linking particular functional groups to IL-1 β pro amino acid side chains or at the N-terminus or C-terminus of the IL-1 β pro polypeptide.

Other derivatives of IL-1 β pro within the scope of this invention include covalent or aggregative conjugates of IL-1 β pro or its fragments with other proteins or polypeptides, such as by synthesis in recombinant culture as N-terminal or C-terminal fusions. For example, the conjugated polypeptide may be a signal (or leader) polypeptide sequence at the N-terminal region of IL-1 β pro polypeptide which co-translationally or post-translationally directs transfer of the IL-1 β pro polypeptide from its site of synthesis to a site inside or outside of the cell membrane or wall (e.g., the yeast α -factor leader). IL-1 β pro polypeptide fusions can comprise polypeptides added to facilitate purification and identification of IL-1 β pro (e.g., poly-His). Further, the amino acid sequence of IL-1 β

pro can be linked to the peptide Asp-Tyr-Lys-Asp-Asp-
Asp-Asp-Lys (Hopp et al. BioTechnology 6:1204 (1988)),
which is a highly antigenic sequence and provides an
5 antibody to enable rapid assay and facile purification
of the expressed recombinant polypeptide. This specific
leader sequence is cleaved by bovine mucosal
enterokinase at the residue immediately following the
Asp-Lys pairing. Moreover, fusion polypeptides having
10 this leader sequence at its N-terminal may be resistant
to degradation in E. coli host cells.

The present invention further includes IL-1 β
pro polypeptides with or without associated native-
pattern glycosylation. IL-1 β , pro expressed in yeast or
15 mammalian expression systems (e.g., COS-7 cells) may be
similar or significantly different in molecular weight
and glycosylation pattern than the native human IL-1 β
pro polypeptide. This depends upon the choice of
expression system. Expression of IL-1 β pro polypeptides
20 in bacterial expression systems, such as E. coli,
provides non-glycosylated molecules.

Functional mutant analogs of human IL-1 β pro
can be synthesized, for example, with inactivated N-
glycosylation sites by oligonucleotide synthesis and
25 ligation or by site specific mutagenesis techniques.
The IL-1 β pro derivatives can be expressed in
homogeneous, reduced carbohydrate form using yeast
expression systems. N-glycosylation sites in eukaryotic
polypeptides are characterized by an amino acid triplet
30 Asn- Φ - Ω where Φ is any amino acid except Pro and Ω is
Ser or Thr. In this sequence, carbohydrate residues are
covalently attached at the Asn side chain.

IL-1 β pro analogs or derivatives may also be
obtained by mutations of the IL-1 β pro DNA sequence. An
35 IL-1 β pro mutant derivative, as referred to herein, is a

polypeptide substantially homologous to IL-1 β pro but which has an amino acid sequence different from native IL-1 β pro because of a deletion, insertion or substitution.

5 IL-1 β pro is expressed from a mammalian gene, presumably encoded by one or more multi-exon genes. The present invention further includes alternative mRNA constructs which can be attributed to different mRNA splicing events following transcription, and which share
10 regions of identity or similarity with the cDNA's disclosed herein.

Bioequivalent analogs of IL-1 β pro polypeptides (defined as polypeptides having IL-1 β pro biological activity) can be constructed, for example, by
15 making various substitutions of amino acid residues or sequences, or by deleting terminal or internal residues or sequences not needed for biological activity. For example, Cys residues can be deleted or replaced with other amino acids to prevent formation of incorrect
20 intramolecular disulfide bridges upon renaturation. Other approaches to mutagenesis involve modification of dibasic amino acid residues to enhance expression in yeast systems in which KEX2 protease activity is present.

25 Generally, substitutions are made conservatively by substituting an amino acid having physiochemical characteristics resembling those of the replaced residue. Further substitutions may be outside of the "core" sequence needed for IL-1 β pro biological
30 activity. Subunits of IL-1 β pro may be constructed by deleting terminal or internal residues or sequences. The resulting polypeptide should have IL-1 β pro biological activity as defined herein.

The terms "IL-1 β pro", "human IL-1 β protease"
35 include, but are not limited to, analogs or subunits of

IL-1 β pro which are substantially similar to human IL-1 β pro and/or which exhibit the substrate-specific proteolytic biological activity associated with IL-1 β pro as described herein.

5 The term "substantially similar", when used to describe amino acid sequences, means that a particular sequence may vary from a disclosed reference sequence by one or more substitutions, deletions, or additions. However, the net effect is the same protease biological
10 activity characteristic of the reference human IL-1 β pro polypeptide. For example, a derivative can have a truncated sequence comprising a "core region" or a sequence of amino acids necessary for the specific protease biological activity characteristic of IL-1 β
15 pro. Substantially similar IL-1 β pro derivatives will be greater than about 30% similar to the corresponding sequence of human IL-1 β pro and have IL-1 β pro biological activity. Polypeptides having amino acid sequences of lesser degrees of similarity but comparable
20 biological activity (including substrate specificity) are considered to be equivalents. More preferably, the derivative polypeptides will have greater than 80% amino acid sequence homology to human IL-1 β pro polypeptide.

 Percent similarity may be determined, for
25 example, by comparing sequence information using a GAP computer program, version 6.0, available from University of Wisconsin Genetics Computer Group. The GAP program uses the alignment method of Needleman and Wunsch (J. Mol. Biol., 48:443 (1970)), as revised by Smith and
30 Waterman [Adv. Appl. Math., 2:482 (1981)]. Briefly, the GAP program defines similarity as the number of aligned symbols which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program
35 include: (1) a weighted comparison matrix for amino

acids [See, Schwartz and Dayhoff, eds. Atlas of Protein
Sequence and Structure, National Biomedical Research
Foundation, pp. 353-58 (1979)]; (2) a penalty of 3.0 for
each gap and an additional 0.10 penalty for each symbol
5 in each gap; and (3) no penalty for end gaps.

"Biologically active", as used herein, refers
to IL-1 β pro biological activity to cleave a particular
amino acid sequence at the peptide bond between an Asp
residue and an Ala or Gly residue.

10 "Recombinant", as used herein, means that a
polypeptide is derived from recombinant (e.g., microbial
or mammalian) expression systems. "Microbial" refers to
bacterial or fungal (e.g., yeast) expression systems.
As a product, "recombinant microbial" defines a
15 polypeptide produced in a microbial expression system
which is substantially free of native endogenous
substances. Polypeptides expressed in most bacterial
expression systems (e.g., *E. coli*) will be free of
glycan. Polypeptides expressed in yeast may have a
20 glycosylation pattern different from that expressed in
mammalian cells.

The IL-1 β pro protease has a highly restricted
substrate specificity. Human precursor IL-1 β
polypeptide has an amino acid sequence His-Asp-Ala-Pro
25 for residues 115-118. Human IL-1 β pro cleaves this
sequence between residues 116 and 117 (Asp-Ala) to form
human mature IL-1 β polypeptide. Changing Asp-116 to Ala
in a human precursor IL-1 β polypeptide by site-directed
mutagenesis prevented cleavage of the mutant IL-1 β
30 polypeptide derivative.

Isolated human IL-1 β pro was able to cleave at
its specific substrate site even when the tertiary
structure of the substrate precursor IL-1 β polypeptide
was altered by denaturing the substrate polypeptide in
35 boiling water. Precursor human IL-1 β was denatured by

boiling a solution of precursor IL-1 β for fifteen minutes. Denaturation had little effect on the ability of human IL-1 β pro to be able to cleave human precursor IL-1 β into mature IL-1 β . Thus, the tertiary structure of the substrate polypeptide does not significantly contribute to the reaction with the enzyme IL-1 β pro.

IL-1 β pro biological activity was determined by a protease assay. As the IL-1 β pro enzyme is salt sensitive, samples having a salt concentration greater than 50 mM were initially desalted. Samples can be desalted, for example, by applying 100 μ l of sample to a pre-spun 1 ml Biogel P-6DG (Bio-Rad) column, which was equilibrated in 10 mM Tris-HCl, 5mM dithiothreitol, pH 8.1, and centrifuging for 5 minutes at 1876 X g. The assay was conducted by incubating a mixture of five μ l (30 ng) of purified human IL-1 β precursor and 10 μ l of the sample to be tested for IL-1 β protease biological activity for 60 minutes at 37°C. A control sample was similarly incubated to check for endogenous IL-1. The control sample mixture contained 5 μ l of 10mM Tris-HCl, pH 8.1 and 5 mM dithiothreitol instead of IL-1 β precursor. The control sample incubations were terminated by addition of SDS (sodium dodecyl sulfate) in sample buffer followed by five minutes of boiling.

All incubated assay mixtures were electrophoresed on 0.75 mm-thick SDS, 14% polyacrylamide slab gels, using a discontinuous system, such as the one described in Laemmli, Nature, 277:680 (1970). Western blots were performed following electrophoresis by transferring the proteins onto nitrocellulose (Sartorius) and probing using an 20 μ g/ml solution of purified IL-1 β COOH-terminal-specific monoclonal antibody (i.e., 16F5). The blot was developed using Horseradish Peroxidase Color Developing Reagent (Bio

Rad). One hundred ng of purified mature IL-1 β was used as a control 17,500 dalton marker on the Wester blot.

Human IL-1 β pro enzyme was obtained and purified from THP-1 cells obtainable from the American Type Culture Collection (ATCC). Approximately 120
5 liters of cells were cultured and then stimulated for 16 hours with liposaccharide, hydroxyurea and silica as described in Matsushima, Biochemistry, 25:3424 (1986). The cells were harvested by centrifugation, washed in
10 Hanks balanced salt solution, and then recentrifuged. The cells were resuspended in 10 mM Tris-HCl, 5mM dithiothreitol, pH 8.1 at a density of 10⁸/ml. The suspended cells were frozen and thawed three times and the lysates stored at -80°C until further use. Prior to
15 purification, the lysates were thawed and then centrifuged for 20 minutes at 47,800 X g at 4°C. The supernatant was taken for further purification. The freeze-thawing procedure repeated four times released over 50% of the IL-1 β pro activity into the supernatant.
20 Additional freeze-thaws did not increase the yield of soluble material.

The human IL-1 β pro polypeptide was purified in a six-step process described below. All the chromatography steps were performed at 4°C using a
25 Pharmacia FPLC System. DEAE-Sephacel, Hydroxyapatite and Blue Agarose gels were pretreated with 0.1% Triton-X-100 and 10% bovine calf serum to prevent non-specific absorption of proteins to the gels. Further, the Blue Agarose column was washed with 8M urea to remove any
30 noncovalently absorbed dye.

1. Approximately 500-600 ml of lysate supernatant was diluted 1:2 in 10mM Tris-HCl and 5mM dithiothreitol, pH 8.1 ("buffer A") to reduce ionic strength of the lysate to <20mM. pH was adjusted to
35 8.1. The diluted lysate supernatant was applied to a

DEAE-Sephacel column (20x4.4 cm, Pharmacia Fine Chemicals), equilibrated with buffer A. The flow rate was 120 ml/hour. The column was washed with two column volumes of buffer A and then eluted with a linear
5 gradient (3 column volumes) ranging from 0 to 300 mM NaCl in buffer A. Fifteen ml fractions were collected, analyzed for IL-1 β pro activity and stored for further purification. The IL-1 β pro activity was eluted with
10 between 0.07 and 0.13 M NaCl. This step removed 79% of the contaminating proteins. The bulk of the contaminating proteins eluted between 0.15 and 0.25 M NaCl. This step was further useful in partially removing endogenous mature IL-1 β , which eluted between 0.06 and 0.11 M NaCl, and endogenous precursor IL-1 β
15 which eluted between 0.12 and 0.18 M NaCl.

2. The pooled active fractions from the DEAE column were diluted in 50 mM potassium phosphate buffer, 5 mM dithiothreitol, pH 7.0 ("buffer B"). A 14 x 3 cm column of hydroxyapatite (HA Ultrogel, IBF Biotechnics)
20 was equilibrated with buffer B. The diluted fractions were applied to the equilibrated hydroxyapatite column at a flow rate of 60 ml/hour. The column was washed with 2 column volumes of buffer B and then eluted with a linear gradient (4 column volumes) ranging from 50-200
25 mM potassium phosphate. Fractions were collected as 10 ml volumes, analyzed for IL-1 β pro activity, and stored for further purification. IL-1 β pro eluted between 0.085 and 0.113 M potassium phosphate. Forty percent of the contaminating polypeptides eluted before the
30 protease and 40% eluted later than the protease. Further, endogenous mature IL-1 β eluted between 0.05 and 0.08 M potassium phosphate.

3. A 20 x 1.6 cm Blue Agarose column (Gibco-BRL) was equilibrated with buffer A. Fractions from the
35 hydroxyapatite column with activity were diluted 1:3 in

buffer A to reduce ionic strength to 30mM. This was necessary in order to allow IL-1 β pro to bind to the column. Diluted fractions were applied to the Blue Agarose column at a 30 ml/hour rate. The column was washed with three column volumes of buffer A. The proteins were eluted with five column volumes of a linear gradient ranging from 0.1 to 1 M NaCl in buffer A. Ten ml fractions were collected, analyzed for IL-1 β pro activity and stored for further purification. IL-1 β pro was eluted with 0.5 to 0.68 M NaCl. Eighty percent of the contaminating proteins were removed in this step, with 20% eluting earlier and the remaining 60% remaining bound to the column.

4. A 95 x 2.5 cm Sephadex G-75 column (Pharmacia Fine Chemicals) was equilibrated in buffer A and initially calibrated with ferritin (MW 400,000), ovalbumin (MW 43,000), soybean trypsin inhibitor (MW 20,000) and DNP-aspartic acid (MW 300). The Blue Agarose column fractions containing protease activity were pooled and concentrated on a Centriprep-10 concentrator (Amicon) to a volume of approximately 2 ml and then applied to the Sephadex G-75 column. Proteins were eluted with buffer A at a flow rate of 20 ml/hr. Four ml fractions were collected and the fractions containing protease activity were pooled for further purification. IL-1 β pro activity was eluted with between 196 and 220 ml. This position is identical to the elution position of soybean trypsin inhibitor, which suggests that human IL-1 β pro has a molecular weight of about 20,000 daltons. This step removed over 90% of the contaminating proteins from the preparation. Thus, through the Sephadex step, more than 99.8% of the starting protein contaminants have been separated from IL-1 β pro. However, PAGE (polyacrylamide gel electrophoresis) analysis of the fractions still

revealed several protein bands that did not correlate with IL-1 β pro biological activity.

5 5. Fractions from the Sephadex column which contained protease activity were pooled and the pool was concentrated on pretreated Centriprep 10 Concentrators to a 500 μ l volume. Since protein concentration of the Sephadex pool was low (<30 μ g/ml), pretreatment of the centripregs with bovine serum albumin reduced loss of IL-1 β pro activity during concentration. Extensive washing of the treated centripregs prior to use prevented contamination of samples with albumin. Pretreatment was accomplished by centrifuging 15 ml of 1% bovine serum albumin (BSA) in centripregs for 30 minutes, decanting the remaining solution, and washing with 10 mM Tris-HCl. A Mono P5/20 FPLC chromatofocusing column (Pharmacia Fine Chemicals) was equilibrated with 25 mM Tris-acetate and 5 mM dithiothreitol, pH 8.3 buffer. The concentrated solution was mixed (1:1 v/v) with 500 μ l of 25 mM Tris-acetate and 5 mM dithiothreitol, pH 8.3 and applied to the Mono P5/20 FPLC column. Proteins were eluted with Polybuffer 96:Polybuffer 74 (3:7) pH 5.0 (Pharmacia) at a 15 ml/hour flow rate. One ml fractions were collected and analyzed for pH and biological protease activity. This chromatofocusing step increased the purity of IL-1 β pro a further 100 fold and allowed for the visualization of a single protein band that correlated with IL-1 β pro biological activity. IL-1 β pro was eluted off the chromatofocusing column between pH 6.95 and 6.70. The fractions were concentrated on BSA-pretreated Centricon 10 Concentrators (Amicon) from 1 μ l to 50 μ l.

35 6. The fractions were subjected to electrophoresis on a polyacrylamide gel (PAGE), followed by electroblotting onto polyvinyl difluoride membrane paper (PVDF, Millipore Immobilon-P®) at 300 mA for 30

minutes. The PVDF membrane was stained with Coomassie Blue. There were five major bands with molecular weights of approximately 45,000, 43,000, 36,000, 22,000 and 18,000 daltons. The 22,000 dalton band correlated with IL-1 β pro activity and was sequenced.

The N-terminal sequence of the 22,000 dalton band yielded an amino acid sequence described herein. A mature human IL-1 β pro cDNA or an active fragment thereof was cloned using this N-terminal amino acid sequence and a three-stage polymerase chain reaction (PCR) procedure. In the first stage PCR procedure, fully degenerate PCR primers were designed and made from the N-terminal amino acid sequence. The degenerate primers were used to amplify IL-1 β pro-specific sequences from a cDNA library prepared from THP-1 cell mRNA. A random primed first strand THP-1 cDNA library was constructed according to supplier instructions (Amersham). A mixed oligonucleotide primed amplification was carried out according to the procedure described in Lee et al. "cDNA Cloning Using Degenerate Primers" in PCR Protocols (Innis, Gelfand, Sninsky and White eds.) Academic Press, Inc. New York pp. 46-53 1990. Primer #1 was designed to cross-hybridize to IL-1 β pro DNA (nucleotides 1-17) and to contain an Eco RI restriction site. Primer #1 had the sequence:

5'-GTCGAATTCAA(T/C)CCNGCNATGCCNAC-3'

(Seq. I.D. No. 9).

Primer #2 was designed to cross-hybridize to IL-1 β pro DNA (complementary to nucleotides 31-47 and contain an Xba I restriction site. Primer #2 had the sequence:

5'-GTCTCTAGAAG(T/C)TTNAC(A/G)TTNCC(T/C)TC-3'

(Seq. I.D. No. 10).

PCR amplification was performed with thermus aquatius polymerase (Perkin-Elmer Cetus) in 100 μ l of

buffer for 30 cycles as described in Lee et al., infra.
A 63 bp amplified fragment was obtained from PCR
amplification. This amplified fragment was subcloned
into a pGem-4 vector (Promega). DNA sequence analysis
of 10 isolates indicated that this fragment encoded the
first 16 amino acids of the N-terminus of IL-1 β pro as
determined by purification and N-terminal sequence
analysis.

The second stage of the PCR procedure made
Primer #3 composed of nucleotides 1-17 (Figure 1) and a
Not I restriction site and Primer #4 containing 20 T
residues and a Not I restriction site. Primers #3 and
#4 were added to the THP-1 cDNA library described above
and PCR amplified for 6 cycles at 94°C for 1 minute,
50°C for 1 minute and 72°C for 1 minute. Southern
analysis of the PCR amplified clone using a 17 base
oligonucleotide probe (complementary to nucleotides 16-
32 in Figure 1) found a band at approximately 1000 bp
that was also found to possess IL-1 β pro biological
activity. The 1000 bp DNA was gel purified, subjected
to a similar second round of PCR and subcloned into
pGem-5 for sequencing. The nucleotide sequence of this
clone is shown in Figure 1.

In the third stage of PCR cloning, full length
IL-1 β pro clones were isolated from a cDNA library
prepared from peripheral blood neutrophils. We found
that neutrophils expressed IL-1 β pro mRNA. We isolated
two clones (p48 and p214) with IL-1 β pro specific
inserts of 1367 and 1360 base pairs, respectively. The
DNA sequence shown in Figure 1 is a composite of all the
IL-1 β pro clones. The amino acids encoded by all of the
IL-1 β pro clones we found were identical.

IL-1 β pro cDNA is approximately 1373 base
pairs in length, including a stretch of A nucleotides
corresponding to the poly (A) tail of mRNA. These A

residues are preceded by two polyadenylation signals, AATAA, at 1316 and 1335 base pair. The sequence has an open reading frame of 404 amino acids, starting with an initiator Met codon at nucleotide 18 and ending with a termination codon at nucleotide 1230. Initiation of translation could also begin with an in-frame Met codon at nucleotide 66. Both initiator Met codons have consensus Kozak translation initiation sequences. Polypeptides initiated with the Met residue at position 51 also have biological activity.

IL-1 β pro is a cytoplasmic enzyme. As the purified enzyme N-terminal amino acid is Asn (120), the protease undergoes N-terminal processing resulting in removal of 119 amino acids or 69 amino acids if the alternate initiator codon is used. Deletion analysis has indicated that at least 107 amino acids are removed from the C-terminus. However, it appears that the full C-terminus is necessary for proper folding of the protease before approximately 107 C-terminal amino acids can be removed to insure biological activity for the protease.

The DNA sequence shown in Figure 1 was expressed in a mammalian cell (e.g., COS-7 cells). For mammalian cell expression, synthetic oligonucleotide primers were made to amplify the entire coding domain of IL-1 β pro. The 5' primer

(5'-ATATCGGTACCGCCTCCAGCATGCCTCCGGCAATGCCCACATC-3')

(Seq. I.D. No. 11)

contained an Asp 718 restriction site and an initiator Met residue fused to the N-terminus of the enzyme (nucleotides 1-20).

The 3' primer

(5'-CTGCTAGATCTGCCCGCAGACATTCATACAG-3')

(Seq. I.D. No. 12)

contains a Bgl II restriction site and is complementary to nucleotides 883-902 of Figure 1. The PCR generated fragment was ligated into pDC303 mammalian vector, as described in Mosley et al., Cell, 59:335-348 (1989).

5 Human IL-1 β pro is preferably produced by recombinant DNA techniques. A recombinant DNA expression system inserts a clone encoding human IL-1 β pro polypeptide or a derivative thereof with biological activity into an expression vector. The expression
10 vector is inserted into a host cell. The host cell's protein synthesis machinery synthesizes the recombinant human IL-1 β pro polypeptide.

Suitable host cells for expression of mammalian IL-1 β pro polypeptides or derivatives thereof
15 include prokaryotes, yeast or higher eukaryotic cells under the control of appropriate promoters. Prokaryotes include gram negative or gram positive organisms, for example E. coli or bacilli. Suitable prokaryotic hosts cells for transformation include, for example, E. coli,
20 Bacillus subtilis, Salmonella typhimurium, and various other species within the genera Pseudomonas, Streptomyces, and Staphylococcus. Higher eukaryotic cells include established cell lines of mammalian origin as described below. Cell-free translation systems could
25 also be employed to produce mammalian IL-1 β pro polypeptides or derivatives thereof using RNAs derived from the DNA constructs disclosed herein. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are
30 described, for example, in Pouwels et al., Cloning Vectors: A Laboratory Manual, Elsevier, New York, (1985).

When an IL-1 β pro polypeptide or derivative thereof is expressed in a yeast host cell, the
35 nucleotide sequence (e.g., structural gene) that codes

on expression for an IL-1 β pro polypeptide or derivative thereof may include a leader sequence. The leader sequence enables improved extracellular secretion of translated polypeptide by a yeast host cell.

5 Alternatively, in a prokaryotic host cell, such as E. coli, the IL-1 β pro polypeptide or derivative thereof may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in a prokaryotic host cell. The N-terminal Met may be
10 cleaved from the expressed recombinant IL-1 β pro polypeptide or derivative thereof. Moreover, prokaryotic host cells may be used for expression and disulfide processing.

 The recombinant expression vectors carrying
15 the recombinant IL-1 β pro structural gene nucleotide sequence or derivative thereof are transfected or transformed into a substantially homogeneous culture of a suitable host microorganism or mammalian cell line. Examples of suitable host cells include bacteria such as
20 E. coli, yeast such as S. cerevisiae, or a mammalian cell line such as Chinese Hamster Ovary (CHO) cells.

 Transformed host cells are cells which have been transformed or transfected with IL-1 β pro or a derivative thereof structural gene nucleotide sequences.
25 Expressed IL-1 β pro polypeptides will be located within the host cell and/or secreted into culture supernatant, depending upon the nature of the host cell and the gene construct inserted into the host cell. Expression
30 vectors transfected into prokaryotic host cells generally comprise one or more phenotypic selectable markers. A phenotypic selectable marker is, for example, a gene encoding proteins that confer antibiotic resistance or that supply an autotrophic requirement, and an origin of replication recognized by the host to
35 ensure amplification within the host.

Other useful expression vectors for prokaryotic host cells include a selectable marker of bacterial origin derived from commercially available plasmids. This selectable marker can comprise genetic elements of the cloning vector pBR322 (ATTC 37017). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells. The pBR322 "backbone" sections are combined with an appropriate promoter and an IL-1 β pro structural gene sequence. Other commercially vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, WI, USA).

Promoter sequences are commonly used for recombinant prokaryotic host cell expression vectors. Common promotor sequences include β -lactamase (penicillinase), lactose promoter system (Chang et al., Nature, 275:615, 1978; and Goeddel et al., Nature, 281:544, 1979), tryptophan (trp) promoter system (Goeddel et al., Nucl. Acids Res., 8:4057, 1980; and EPA 36,776) and tac promoter (Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, p.412, 1982). A particularly useful prokaryotic host cell expression system employs a phage λ P_L promoter and a cI875ts thermolabile repressor sequence. Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the λ P_L promoter include plasmid pHUB2 (resident in E. coli strain JMB9 (ATCC 37092)) and pPLc28 (resident in E. coli RR1 (ATCC 53082)).

Human IL-1 β pro polypeptides and derivative polypeptides may be expressed in yeast host cells, preferably from the Saccharomyces genus (e.g., S. cerevisiae). Other genera of yeast, such as Pichia or Kluyveromyces, may also be employed. Yeast vectors will

often contain an origin of replication sequence from a 2 μ yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, and sequences for transcription termination.

5 Preferably, yeast vectors include an origin of replication sequence and selectable marker. Suitable promoter sequences for yeast vectors include promoters for metallothionein, 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073, (1980)] or other
10 glycolytic enzymes [Hess, et al., J. Adv. Enzyme Reg., 7:149, (1968); and Holland et al., Biochem. 17:4900, (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-
15 phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other suitable vectors and promoters for use in yeast expression are further described in Hitzeman, EP-A-73,657.

20 Yeast vectors can be assembled, for example, using DNA sequences from pBR322 for selection and replication in E. coli (Amp^r gene and origin of replication). Other yeast DNA sequences that can be included in a yeast expression construct include a
25 glucose-repressible ADH2 promoter and α -factor secretion leader. The ADH2 promoter has been described by Russell et al., [J. Biol. Chem., 258:2674, (1982)] and Beier et al., [Nature, 300:724, (1982)]. The yeast α -factor leader sequence directs secretion of heterologous
30 polypeptides. The α -factor leader sequence is often inserted between the promoter sequence and the structural gene sequence. [See, e.g., Kurjan et al., Cell, 30:933, (1982); and Bitter et al., Proc. Natl. Acad. Sci. USA, 81:5330, (1984).] A leader sequence may
35 be modified near its 3' end to contain one or more

restriction sites. This will facilitate fusion of the leader sequence to the structural gene.

Yeast transformation protocols are known to those of skill in the art. One such protocol is described by Hinnen et al., Proc. Natl. Acad. Sci. USA, 75:1929, (1978). The Hinnen et al., protocol selects for Trp⁺ transformants in a selective medium, wherein the selective medium consists of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10µg/ml adenine and 20 µg/ml uracil.

Yeast host cells transformed by vectors containing ADH2 promoter sequence may be grown for inducing expression in a "rich" medium. An example of a rich medium is one consisting of 1% yeast extract, 2% peptone, and 1% glucose supplemented with 80 µg/ml adenine and 80 µg/ml muacil. Derepression of the ADH2 promoter occurs when glucose is exhausted from the medium.

Mammalian or insect host cell culture systems could also be employed to express recombinant IL-1β pro polypeptide or derivatives thereof. Examples of suitable mammalian host cell lines include the COS-7 lines of monkey kidney cells [Gluzman, Cell, 23:175, (1981)], L cells, C127 cells, 3T3 cells, Chinese hamster ovary (CHO) cells, HeLa cells, and BHK cell lines. Suitable mammalian expression vectors include nontranscribed elements such as an origin of replication, a promoter sequence, an enhancer linked to the structural gene, other 5' or 3' flanking nontranscribed sequences, such as ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences.

Transcriptional and translational control sequences in mammalian host cell expression vectors may be provided by viral sources. For example, commonly

used mammalian cell promoter sequences and enhancer sequences are derived from Polyoma, Adenovirus 2, Simian Virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites may be used to provide the other genetic elements required for expression of a structural gene sequence in a mammalian host cell. Viral early and late promoters are particularly useful because both are easily obtained from a viral genome as a fragment which may also contain a viral origin of replication [Fiers et al., Nature, 273:113, (1978)]. Smaller or larger SV40 fragments may also be used, provided the approximately 250 bp sequence extending from the Hind III site toward the BglI site located in the SV40 viral origin of replication site is included.

Further, mammalian genomic IL-1 β pro promoter, control and/or signal sequences may be utilized, provided such control sequences are compatible with the host cell chosen. Exemplary vectors can be constructed as disclosed by Okayama and Berg [Mol. Cell. Biol., 3:280, (1983)].

Purified human IL-1 β pro polypeptides or derivatives thereof are prepared by culturing transformed host cells under culture conditions necessary to express IL-1 β pro polypeptides or derivatives thereof. The expressed polypeptides are purified from culture media or cell extracts. For example, supernatants from cultured transformed host cells can secrete recombinant IL-1 β pro polypeptide into culture media. The IL-1 β pro polypeptide or derivative thereof is concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a

purification matrix. For example, a suitable purification matrix is an IL-1 β pro inhibitor or an antibody molecule specific for an IL-1 β pro polypeptide or derivative thereof and bound to a suitable support.

5 Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendent diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification.

10 Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred.

15 Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify an IL-1 β pro polypeptide composition. Some or all of the foregoing purification
20 steps, in various combinations, can also be employed to provide a homogeneous recombinant protein. Alternatively, some or all of the steps used in the purification procedure described herein can also be employed.

25 Recombinant polypeptide produced in bacterial culture is usually isolated by initial disruption of the host cells, extraction from cell pellets of an insoluble polypeptide, or from the supernatant of a soluble polypeptide, followed by one or more concentration,
30 salting-out, ion exchange or size exclusion chromatography steps. Finally, reverse phase high performance liquid chromatography (RP-HPLC) can be employed for final purification steps. Microbial cells can be disrupted by any convenient method, including

freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

Transformed yeast host cells generally express IL-1 β pro polypeptide as a secreted polypeptide. This
5 simplifies purification. Secreted recombinant polypeptide from a yeast host cell fermentation can be purified by methods analogous to those disclosed by Urdal et al., [J. Chromatog., 296:171, (1984)]. Urdal et al., describe two sequential, reversed-phase HPLC
10 steps for purification of recombinant human IL-2 on a preparative HPLC column.

II. Interleukin 1 β Protease Inhibitors

The inhibitors of the present invention are
15 substituted compounds comprising an amino acid sequence of from 1 to about 5 amino acid residues having an N-terminal blocking group and a C-terminal Asp residue connected to an electronegative leaving group, wherein the amino acid sequence corresponds to at least a
20 portion of the sequence Ala-Tyr-Val-His-Asp, which sequence represents the sequence of residues 112 to 116 of preIL-1 β .

The amino acid sequence of preIL-1 β is presented in Seq. I.D. No. 3 and in Figure 2 taken from
25 March, C.J. et al., Nature (London), 315(6021):641-647 (1985). Mature IL-1 β is represented by the C-terminal 153 amino acid residues of preIL-1 β . Thus, the N-terminal of IL-1 β is the Ala residue at position 117 of Seq. I.D. No. 3.

30 Amino acid residues can be expressed by the full name (e.g., alanine) or by the three letter designation (e.g., Ala). This application will use the three letter designation.

The naturally occurring amino acids are the L isomers and are so indicated without any isomeric (e.g., L or D) designation. The D isomers are so indicated.

5 As used herein, the phrase "corresponds to" means that a particular sequence of an inhibitor compound may differ from the disclosed sequence by one or more conservative substitutions so long as such substitutions do not materially alter the inhibitory activity of the compounds of the present invention.

10 Examples of substitutions that do not materially alter inhibitory activity are replacement of the Ala at position 112 of Seq. I.D. No. 3 with Ser or Gly; replacement of the Tyr at position 113 of Seq. I.D. No. 3 with Phe; replacement of the Val at position 114
15 of Seq. I.D. No. 3 with Leu, Ile or Met and replacement of the His at position 115 of Seq. I.D. No. 3 with Phe, Pro, a positively charged amino acid such as Lys, Arg, His or Tyr, or the use of D isomers.

20 The C-terminal amino acid residue of the inhibitor compounds of the present invention is aspartic acid (Asp). Asp has a side chain of the formula $\text{CH}_2\text{-COOH}$. Preferably, the Asp side chain carboxyl group is protected to facilitate synthesis of the compounds of the present invention.

25 Asp side chain protection groups include, for example, a benzyl, substituted benzyl, formyl methyl or t-butyl moiety. The benzyl substituents increase the acid lability of the Asp side chain protecting moiety. Exemplary substituted benzyls are 2,4,6-trimethyl benzyl
30 and 4-methoxybenzyl.

In a preferred embodiment, the Asp side chain protecting moiety is connected to the Asp side chain via an ester linkage, which linkage is subject to cleavage by naturally occurring intracellular esterase enzymes.
35 In this way, the protected Asp with high lipid

5 As used herein, the phrase "N-terminal
blocking group" refers to chemical groups attached to
the amino group of the N-terminal amino acid residue of
the sequences of the present invention. Such blocking
groups are well known and readily apparent to those of
10 skill in the art. The Peptides, ed. by Gross and
Meienhofer, Academic Press, New York, pp. 3-81 (1981).
N-terminal blocking groups have been utilized with other
types of protease inhibitors. See, e.g., U.S. Patent
Nos. 4,652,552 and 4,636,492.

20 The compounds of the present invention inhibit the catalytic activity of IL-1 β pro in a reversible or an irreversible fashion. As used herein, "irreversible" means the formation of a covalent bond between the enzyme and the inhibitor.

The compounds of the present invention have the formula:

$$Z-Q_2-Asp-Q_1$$

where Z is an N-terminal blocking group;
Q₂ is 0 to about 4 amino acids such that the sequence
Q₂-Asp corresponds to at least a portion of the sequence
Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D.
5 No. 3; and
Q₁ is an electronegative leaving group.

In a preferred embodiment, Z is C₁-C₆ alkyl,
benzyl, acetyl, C₁-C₆ alkoxy carbonyl, benzyloxy carbonyl
or C₁-C₆ alkyl carbonyl. As used herein, "alkyl" refers
10 to linear or branched chains having 1 to 6 carbon atoms,
which may be optionally substituted as herein defined.
Representative alkyl groups include methyl, ethyl,
propyl, isopropyl, butyl, pentyl, hexyl and the like.
In a more preferred embodiment, Z is t-butoxycarbonyl
15 (t-Boc), acetyl or benzyloxy carbonyl (Cbz).

Q₂ is preferably 1 amino acid. Preferably Q₂
is His, Phe, Pro, or Tyr. Most preferably, Q₂ is His or
Phe.

Q₁ is preferably an aldehyde, a diazoalkyl
20 ketone or a haloalkyl ketone. As used herein in
reference to electronegative leaving groups, "alkyl"
refers to linear or branched chain radicals having 1 to
3 carbon atoms, which may be optionally substituted as
herein defined. Representative alkyl groups include
25 methyl, ethyl, propyl and the like. More preferably, Q₁
is an aldehyde or fluoromethyl (CH₂F) ketone.

The compounds of the present invention are
made by techniques generally corresponding to methods
known and readily apparent to those of skill in the art.
30 See, e.g., Kettner, C.A. et al., Arch. Biochem.
Biophys., 162:56 (1974); U.S. Patent No. 4,582,821; U.S.
Patent No. 4,644,055; Kettner, C.A. et al., Arch.
Biochem. Biophys., 165:739 (1974); Dakin, H.D. and West,
R., J. Biol. Chem., 78:91 (1928); Rasnick, D., Anal.
35 Biochem., 149:461 (1985).

Compounds having a fluoromethyl electronegative leaving group are preferably synthesized by the Rasnick procedure.

5 Compounds having a non-fluoro, haloalkyl ketone electronegative leaving group are synthesized in accordance with the Kettner procedure. An N-blocked amino acid or peptide is reacted with N-methylmorpholine and an alkyl, non-fluoro haloformate to generate a peptide-acid anhydride. The anhydride is then reacted
10 with a diazoalkane in an inert, aprotic solvent to form a peptide-diazomethane ketone. The diazomethane ketone is then reacted with an anhydrous solution of HCl, HBr or HI to produce the desired N-blocked, C-terminal haloalkyl ketone peptide or amino acid.

15 Compounds having a fluoroalkyl ketone electronegative leaving group are synthesized in accordance with a Rasnick procedure. An N-blocked peptide is reacted with fluoroacetic anhydride and a trialkylamine in an organic solvent to form a peptide-anhydride. The anhydride is then reacted with a
20 catalyst such as 4-dimethylaminopyridine and the reaction mixture maintained at about 25°C for about two hours to allow for CO₂ evolution. The reaction mixture is then extracted with an organic solvent and the
25 organic phase washed and dried. The organic solvent is removed to form an oil, which is then applied to a silica gel column. The N-blocked, fluoroalkyl ketone peptide is then eluted from the gel and purified.

30 Compounds having a fluoroalkyl ketone electronegative leaving group can be extended in the N-terminus direction by removing the N-terminal blocking group and coupling the deprotected compound with other protected amino acids. Bodanszky, The Practice of Peptide Synthesis, Springer-Verlag, Berlin (1984).
35 Alternatively, deprotected compounds are acetylated to

yield compounds having an N-terminal acetyl protecting group. Stewart et al., solid Phase Peptide Synthesis, Pierce Chemical Co., Rockford, IL. (1984).

5 III. Methods of Treatment and Pharmaceutical
 Compositions

 The present invention provides methods of
using therapeutic compositions comprising an effective
amount of IL-1 β pro polypeptides and derivatives thereof
10 in a suitable diluent and carrier. For therapeutic use,
purified IL-1 β pro or a biologically active derivative
thereof is administered to a patient, preferably a
human, for treatment in a manner appropriate to the
indication. Thus, for example, IL-1 β pro compositions
15 administered to suppress autoimmunity can be given by
bolus injection, continuous infusion, sustained release
from implants, or other suitable technique. Typically,
an IL-1 β pro therapeutic agent will be administered in
the form of a pharmaceutical composition comprising
20 purified polypeptide in conjunction with physiologically
acceptable carriers, excipients or diluents. Such
carriers will be nontoxic to patients at the dosages and
concentrations employed. Ordinarily, the preparation of
such compositions entails combining IL-1 β pro with
25 buffers, antioxidants such as ascorbic acid, low
molecular weight (less than about 10 residues)
polypeptides, proteins, amino acids, carbohydrates
including glucose, sucrose or dextrans, chelating agents
such as EDTA, glutathione and other stabilizers and
30 excipients. Neutral buffered saline or saline mixed
with conspecific serum albumin are exemplary appropriate
diluents.

 The inhibitor compounds of the present
invention are useful in inhibiting the physiological
35 actions of interleukin 1 β by preventing formation of

biologically active IL-1 β . The inhibition of IL-1 β pro results in a decrease in active IL-1 β levels and a concomitant increase in preIL-1 β , which compound is biologically inactive.

5 The inhibitor compounds of the present invention are also useful in treating dysfunctional states, such as autoimmune disease-associated inflammation, often mediated by increased IL-1 activity.

10 Mammals needing treatment for an inflammatory disorder or prevention of an autoimmune condition are administered effective amounts of the inhibitor compounds of this invention either alone or in the form of a pharmaceutical composition.

15 The pharmaceutical compositions of the present invention include one or more of the compounds of this invention formulated into compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants or vehicles which are collectively referred to herein as carriers, for parenteral injection, for oral
20 administration or solid or liquid form, for rectal or topical administration, and the like.

 The compositions can be administered to humans and animals either orally, rectally, parenterally (intravenously, intramuscularly or subcutaneously)
25 intracisternally, intravaginally, intraperitoneally, locally (powders, ointments or drops), or as a buccal or nasal spray.

 Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous
30 or nonaqueous solutions, dispersions, suspension or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols
35 (propyleneglycol, polyethyleneglycol, glycerol, and the

like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

If desired, and for more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose,

alignates, gelatin, polyvinylpyrrolidone, sucrose and
acadia, (c) humectants, as for example, glycerol, (d)
disintegrating agents, as for example, agar-agar,
calcium carbonate, potato or tapioca starch, alginic
5 acid, certain complex silicates and sodium carbonate,
(e) solution retarders, as for example paraffin, (f)
absorption accelerators, as for example, quaternary
ammonium compounds, (g) wetting agents, as for example,
cetyl alcohol and glycerol monostearate, (h) adsorbents,
10 as for example, kaolin and bentonite, and (i)
lubricants, as for example, talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium
lauryl sulfate or mixtures thereof. In the case of
capsules, tablets and pills, the dosage forms may also
15 comprise buffering agents.

Solid compositions of a similar type may also
be employed as fillers in soft and hard-filled gelatin
capsules using such excipients as lactose or milk sugar
as well as high molecular weight polyethyleneglycols,
20 and the like.

Solid dosage forms such as tablets, dragees,
capsules, pills and granules can be prepared with
coatings and shells, such as enteric coatings and others
well known in the art. They may contain opacifying
25 agents, and can also be of such composition that they
release the active compound or compounds in a certain
part of the intestinal tract in a delayed manner.
Examples of embedding compositions which can be used are
polymeric substances and waxes.

30 The active compounds can also be in micro-
encapsulated form, if appropriate, with one or more of
the above-mentioned excipients.

Liquid dosage forms for oral administration
include pharmaceutically acceptable emulsions,
35 solutions, suspensions, syrups and elixirs. In addition

to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan or mixtures of these substances, and the like.

Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

Compositions for rectal administrations are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.

Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any needed preservatives, buffers

or propellants as may be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

5 The compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid
10 crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to the IL-1 β pro inhibiting compounds of the
15 present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.

 Methods for form liposomes are known in the
20 art. See, for example, Methods in Cell Biology, Ed. by Prescott, Volume XIV, Academic Press, New York, N. Y. p.33 et seq., (1976).

 Actual dosage levels of active ingredient in the compositions of the present invention may be varied
25 so as to obtain an amount of active ingredient that is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, on the route of
30 administration, on the desired duration of treatment and other factors.

 The total daily dose of the inhibitor compounds of this invention administered to a host in single or divided doses may be in amounts, for example,
35 of from about 0.1 mg to about 160.0 mg per kilogram of

body weight. Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the body weight, general health, sex, diet, time and route of administration, rates of absorption and excretion, combination with other drugs and the severity of the particular disease being treated.

The following examples are for the purposes of illustration and not by way of limitation.

EXAMPLES

EXAMPLE 1: Substrate specificity of IL-1 β pro

This example illustrates the range of substrate specificity of purified human IL-1 β pro enzyme to cleave a group of amino acid sequences. A variety of peptide substrates were prepared featuring changes in individual amino acids in the region corresponding to the cleavage site in human precursor IL-1 β (His 115 to Pro 118). The reactivity of the peptide substrates was expressed relative to the peptide corresponding to Ala 112 to Ser 121 of the precursor IL-1 β sequence.

Substrate peptides were synthesized by solid phase method [Merrifield, J. Amer. Chem. Soc., 86:304-05 (1964)] using either an Applied Biosystems 430A peptide synthesizer or by the manual T-bag approach of Houghten [Proc. Nat. Acad. Sci. USA, 82:5131-35 (1985)]. 4-Methyl benzhydrylamine resin was used. The substrate peptides were acetylated prior to cleavage from resin, by liquid HF (0°C, 1 hr) in the presence of anisole as scavenger (HF:anisole 9:1). After evaporation of HF, the substrate peptide resin mixtures were washed with diethyl ether and extracted with 15% (w/v) acetic acid,

lyophilized and purified on reverse phase high performance liquid chromatography (RP-HPLC) on a Vydac C18, 2.2cm x 25 cm column. Trifluoroacetic acid (0.1%) in water was solvent A and 0.1% trifluoroacetic acid in acetonitrile was solvent B for the mobile phases.

The purified substrate peptides were characterized by amino acid analysis using a Beckman 6300 system, RP-HPLC and mass spectrometry. Mass spectra were obtained by either fast atom bombardment on a VG Trio-2 system with xenon as the ionizing gas and glycerol/thioglycerol (1:1) as the sample matrix or by ²⁵²Cf plasma desorption mass spectrometry on a Bio-Ion 20 mass spectrometer (See Tsarbopoulos, Peptide Res. 2:258-66 1989). In each case, the mass of the observed peptide substrate corresponded with the theoretical value.

Peptide solutions of standard concentration were prepared by dissolving about 2-3 mg of peptide substrate in water, loading the solution onto a Waters Sep-Pak C18 cartridge and washing three times with 5 ml of water. The peptide substrates were eluted with acetonitrile and then evaporated to dryness. Each substrate was standardized to 1 mM by amino acid analysis prior to use.

Purified human IL-1 β pro enzyme (10 μ l), peptide substrate in water (10 μ l), and 10 mM Tris buffer, pH 8.0 containing 25% v/v glycerol (10 μ l) were mixed and the mixtures were incubated at 37°C for four hours. The reaction was quenched with by adding 1 M glycine/HCl buffer pH 2.0 (10 μ l). The samples were then analyzed using RP-HPLC with a Vydac C18 column (0.46 cm x 25 cm) and eluting with a linear gradient from 100% solvent A to 70% solvent A/30% solvent B over 30 minutes at a flow rate of 1 ml/min. The effluent was monitored at 280 nm absorbing product. A comparison of peak area

of product peptide to that of total peak area of substrate and product yielded the extent of peptide cleavage, because the area under the combined substrate and product peaks was constant and independent of the amount of cleavage by the IL-1 β pro enzyme. Identities of peptide product peaks were confirmed by amino acid analysis and by mass spectrometry.

Table 1 shows the relative reactivities of a series of eight peptide substrates that were subject to digestion by purified IL-1 β pro enzyme.

TABLE 1

	<u>Peptide</u>	<u>Sequence</u>	Reactivity Relative <u>To Peptide 1</u>
15	1	Ala-Tyr-Val-His- Asp-Ala-Pro-Val-Arg-Ser (Seq. I.D. No. 13)	1.00
20	2	Ala-Tyr-Val-His- Asn-Ala-Pro-Val-Arg-Ser (Seq. I.D. No. 14)	<0.01
25	3	Ala-Tyr-Val-His- Glu-Ala-Pro-Val-Arg-Ser (Seq. I.D. No. 15)	<0.05
30	4	Ala-Tyr-Val-His- (D-Asp)-Ala-Pro-Val-Arg-Ser (Seq. I.D. No. 16)	<0.01
	5	Ala-Tyr-Val-His- Asp-Gly-Pro-Val-Arg-Ser (Seq. I.D. No. 17)	3.40
35	6	Ala-Tyr-Val-His- Asp-Val-Pro-Val-Arg-Ser (Seq. I.D. No. 18)	<0.05
40	7	Ala-Tyr-Val-Phe- Asp-Ala-Pro-Val-Arg-Ser (Seq. I.D. No. 19)	0.50
45	8	Ala-Tyr-Val-His- Asp-Ala-Ala-Val-Arg-Ser (Seq. I.D. No. 20)	0.47

The cleavage site can be described with the corresponding human precursor IL-1 β amino acid residues as follows:

P2 P1 P1'P2'

5

His-Asp-Ala-Pro

Changing the L-aspartic acid residue of peptide 1 to either asparagine (peptide 2), glutamic acid (peptide 3) or D-aspartate (peptide 4) has a profound effect on the ability of IL-1 β pro to cleave the substrate. These data establish the requirement of an L-aspartate residue in the P1 position for this enzyme to be able to cleave a substrate.

Peptides 5 and 6 represent changes in the P1' position of the human precursor IL-1 β cleavage site. Replacing alanine with glycine (peptide 5) results in a substrate that is 3.4 times more reactive than peptide 1. However, changing the same residue to a valine (peptide 6) effectively prevents proteolytic cleavage. The fact that with a glycine residue in P1' the peptide is cleaved more readily suggests that the alanine residue in human precursor IL-1 β polypeptide is not critical for substrate binding, while the result with a valine residue in the P1' position indicates low steric tolerance at the P1' position. Thus, it seems unlikely that the IL-1 β pro enzyme or derivatives thereof will cleave anywhere other than between Asp-Gly and Asp-Ala residues.

Peptides 7 and 8 represent changes to the P2 and P2' sites, respectively. Changing the proline of peptide 1 to an alanine yielded a substrate which was still cleaved by human IL-1 β pro but only half as efficiently as the peptide with human IL-1 β native sequence. A similar result was obtained when the histidine of peptide 1 was replaced with a phenylalanine. These data suggest that human IL-1 β pro

enzyme tolerates conservative replacements of both residues and that the P2 and P2' positions are not as vital for activity as the amino acids at the P1 and P1' positions.

EXAMPLE 2: Effect of Substrate Length

This example illustrates the effect of substrate peptide length on the ability of human IL-1 β pro enzyme to cleave peptide substrates. The experiment was conducted as described in Example 1. Five substrate peptides were made that correspond to the amino acid sequence of the IL-1 β pro cleavage site of human precursor IL-1 β . The results are shown in Table 2 below:

Table 2

<u>Peptide</u>	<u>Sequence</u>	<u>Reactivity Relative To Peptide 1</u>
1	Ala-Tyr-Val-His- Asp-Ala-Pro-Val-Arg-Ser- (Seq. I.D. No. 13)	1.00
9	Glu-Ala-Tyr-Val- His-Asp-Ala-Pro- (Seq. I.D. No. 21)	0.74
10	Tyr-Val-His-Asp- Ala-Pro-Val-Arg- (Seq. I.D. No. 22)	2.40
11	Val-His-Asp-Ala- Pro-Val- (Seq. I.D. No. 23)	Not cleaved
12	His-Asp-Ala-Pro- (Seq. I.D. No. 24)	Not cleaved

The eight amino acid peptide (Ac-Tyr-Val-His-Asp-Ala-Pro-Val-Arg-NH₂) is cleaved most efficiently while the four and six amino acid peptides are not cleaved. Thus,

IL-1 β pro has a minimum number of amino acid residues necessary for substrate peptide cleavage.

Example 3: Synthesis of IL-1 β Protease Inhibitors

5 A. Synthesis of Boc-Asp-CH₂F.

A suspension of Boc-Asp-OH (8.11 mmol) and fluoroacetic anhydride (16.2 mmol) in benzene (30 ml) was treated with triethylamine (16.2 mmol) at room temperature. The catalyst 4-dimethylaminopyridine (0.41 mmol) was added to the solution and the reaction stirred for about 2 h at room temperature. About 100 ml benzene was added to the reaction mixture. The organic solution was washed with 1N HCl (2 x 50 ml), saturated NaHCO₃ (2 x 50 ml), and saturated NaCl (2 x 50 ml), followed by drying over anhydrous MgSO₄. The solvent was then removed by evaporation under reduced pressure. The resulting oil was applied to a 2.5 x 80 cm column of silica gel (60-200 mesh). The title compound was eluded with 2% methanol in chloroform.

20 B. Synthesis of Boc-His-Asp-CH₂F, Boc-Tyr-Asp-CHF and Boc-Phe-Asp-CH₂F.

Boc-Asp-CH₂F prepared in accordance with the method of Example 3A above may be dissolved in trifluoroacetic acid (TFA) and the mixture stirred for about 5 minutes at about 23°C. Cold ether may then be added to the mixture. The ether is evaporated and toluene added to co-evaporate residual TFA. The deprotected peptide (H-Asp-CH₂F) is obtained as a TFA salt. The deprotected peptide may then be coupled to a protected amino acid (i.e., Boc-HisOH, Boc-ProOH, Boc-TyrOH, Boc-PheOH) using a standard symmetric anhydride procedure employing dicyclohexylcarbodiimide as a coupling reagent. Bodanszky, supra.

35

C. Synthesis of Ac-His-Asp-CH₂F, Ac-Pro-Asp-CH₂F, Ac-Tyr-Asp-CH₂F and Ac-Phe-Asp-CH₂F.

5 The Boc protecting groups may be removed from the compounds made in accordance with the method of Example 3B using trifluoroacetic acid as described above. Each deprotected compound may then be acetylated with acetic anhydride and diisopropylamine (DIAE) according to standard techniques. Stuart et al., supra.

10 D. Synthesis of Cbz-His-Asp-CH₂F, Cbz-Pro-Asp-CH₂F, Cbz-Tyr-Asp-CH₂F and Cbz-Phe-Asp-CH₂F.

15 The Boc protecting group may be removed from Boc-Asp-CH₂F prepared according to the method of Example 3A using TFA as described above. Benzyloxycarbonyl-protected amino acids (i.e., Cbz-His-OH, Cbz-Phe-OH, Cbz-Tyr-OH, Cbz-Pro-OH) available from commercial sources (Bachem, Philadelphia, PA) can then be coupled to the deprotected Asp using a symmetric anhydride coupling procedure. Bodanszky, supra.

20 **Example 4:** Inhibition of IL-1 β pro Activity

Boc-Asp-CH₂F was tested for its ability to inhibit IL-1 β pro catalyzed degradation of preIL-1 β using an in vitro assay method. Black, et al., 25 J. Biol. Chem., 263(19): 9437 (1988). The results of this study are shown in Figure 2. Boc-Asp-CH₂F was prepared in accordance with the method of example of 1A.

A. Production of preIL-1 β

30 Precursor preIL-1 β polypeptide was obtained from E. coli using standard recombinant DNA techniques. Black, supra. Recombinant preIL-1 β was expressed in E. coli under the control of the phage λ P_L promoter and cI857^{ts} thermolabile repressor. Using standard 35 recombinant DNA techniques, pLNIL-1 β F was constructed by

ligating the following DNA segments: (1) 6160 base pairs of Nco I/Hind III-digested pLNIL-1 β (12) containing the vector (conferring ampicillin resistance), codons 134-269 and 3' noncoding regions of HuIL-1 β ; (2)
5 complementary synthetic oligonucleotides encoding residues 1-6 of IL-1 β and Nco I and Sst I complementary ends; and (3) a 380-base pair Sst I/Hind III restriction fragment from plasmid IL-1 β -6(1) encoding residues 7-133. The ligation mixture was transformed into the
10 tetracycline-resistant host RRI:prK248cI^{ts} (12) and correctly assembled plasmids were identified by restriction analysis of DNA isolated from transformants resistant to both ampicillin and tetracycline. Transformants containing pLNIL-1 β F were tested
15 for the production of preIL-1 β by SDS-PAGE analysis of cultures grown in super induction medium to A₆₀₀ of 0.5 and derepressed for 1-20 h by elevation of temperature from 30° to 42°C. A protein of about 31,000 daltons was apparent in samples from pLNIL-1 β F containing cultures
20 but not in control cultures lacking the IL-1 β coding region. Immuno-dot blot analysis with an anti-IL-1 β monoclonal antibody (MAb) and purified recombinant mature IL-1 β as a standard indicated that the cultures contained approximately 2.5-5.0 μ g/ml of preIL-1 β .

25

B. Extraction of preIL-1 β from E. coli

Cell pellets from 2.5 liters of transferred
E. coli culture were resuspended in 20 ml of 30mM Tris-HCl buffer (pH 9.5) containing 5mM
30 ethylenediaminetetraacetic acid (EDTA), 500 μ g/ml of lysozyme, and 1mM phenylmethanesulfonyl (PMSF). The cell suspensions were homogenized using a Polytron homogenizer (Brinkmann Instruments), rapidly frozen in a Dry Ice/methanol bath, and then thawed. Next, 200 ml of
35 30 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl

and 1 mM PMSF was added to the suspensions, which were then homogenized until a uniform homogenate was obtained. The suspensions were incubated for 30 minutes at 4°C, then centrifuged at 4°C for 60 minutes at 3800 X g. The supernatant fractions were carefully decanted and filtered to remove any particular matter. The pellets were re-extracted in 200 ml of 30mM Tris-HCl buffer (pH 8.0), containing 150 mM NaCl, 8 M urea, and 1 mM PMSF. Since both the Tris and the urea extracts contained substantial amounts of the preIL-1 β , both were purified as described below.

C. Purification of preIL-1 β

All chromatographic procedures were carried out at 4°C. All fractions were assayed for protein concentration, and conductivity was measured where appropriate. After each chromatographic step, fractions were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis SDS-PAGE (with a 10-20% gradient of polyacrylamide), followed by silver staining, and by Western blot using a MAb generated against purified mature IL-1 β .

The extracts were diluted 1:4 in H₂O, the pH was adjusted to 8.1, and the material was loaded at 100 ml/h onto a 25 X 2.5 cm Q-Sepharose column. For the Tris extract, the column was equilibrated in 10 mM Tris-HCl (pH 8.1). For the urea extract, the column was equilibrated in 10 mM Tris-HCl (pH 8.1), 2 M urea. The columns were washed with 8 column volumes of 10 mM Tris-HCl (pH 8.1), and the bound proteins eluted with a linear gradient (three column volumes) ranging from 0 to 1.5 M NaCl in 10 mM Tris-HCl (pH 8.1). Fractions of 7.5 ml were collected and stored at 4°C until the next step of the purification.

The Q-Sepharose fractions containing the preIL-1 β (as determined by Western blot analysis) were pooled and diluted 1:10 in 10mM Tris-HCl (pH 8.1). The column was washed with 4 column volumes of the starting buffer.

The Tris-HCl solution was applied to a 20 X 5 cm column of phenyl-Sepharose CL-4B that had been equilibrated in 10 mM Tris HCl buffer (pH 8.1) containing 0.2 M (NH₄)₂SO₄. The column was washed with 3 column volumes of the starting buffer and then material was eluted initially with 4 column volumes of a decreasing linear gradient of (NH₄)₂SO₄, generated with 0.2 and 0 M solutions in 10mM Tris-HCl buffer (pH 8.1). Finally, the material was eluted with 2 column volumes of 10 mM Tris-HCl (pH 8.1). Fractions containing partially purified preIL-1 β were pooled, dialyzed against PBS, and stored at -70°C until use.

D. Proteolytic Treatment of preIL-1 β

5 μ l of preIL-1 β (about 50 μ g/ml in PBS) was mixed with 10 μ l of purified IL-1 β pro (15-75 μ g/ml in PBS) and incubated at 37°C for 30 minutes. The incubation was terminated by placing the samples on Dry Ice or by the addition of SDS sample buffer. PMSF was then added to a concentration of 1 mM, and the samples were dialyzed against water. After dialysis, the samples were concentrated to dryness in a Speed-Vac concentrator and dissolved in SDS sample buffer.

E. Western Blot Analysis of Proteolytic Products

SDS-PAGE was carried out with 12% polyacrylamide gels. The gels were placed in transfer buffer (0.192 M glycine, 0.025 M Tris-HCl (pH 8.3), 20% v/v methanol), and protein was then electrophoresed onto

nitrocellulose (Sartorius) in a Hoeffler transfer apparatus (1 h at maximum voltage). The nitrocellulose was subsequently placed in 20 mM sodium phosphate, pH 7.4 (PBS) containing 3% bovine serum albumin for at least 15 minutes at room temperature. We used a MAb specific for mature IL-1 β to probe the blot. MAb was added to a concentration of 9 μ g/ml, and the incubation was continued for 30 minutes. The blot was then rinsed three times with PBS and was developed with a solution obtained by mixing 6 mg of horseradish peroxidase developing reagent (Bio-Rad) dissolved in 2 ml methanol and hydrogen peroxide (60 μ l diluted into 10 ml of Tris-buffered saline).

The data show that Boc-Asp-Ch₂F completely inhibits the generation of mature IL-1 β from preIL-1 β at a concentration of 5 μ M and partially inhibits generation of mature IL-1 β at a concentration of 1 μ M.

Example 5: Biological activity of IL-1 β pro when transfected into COS-7 cells.

We inserted a cDNA corresponding to amino acids 120 to 404 into a mammalian cell expression vector (pDC303). This plasmid was co-transfected into COS-7 cells (monkey kidney) with a second mammalian expression plasmid containing a cDNA encoding precursor IL-1 β . After two days, cells were radiolabeled with ³⁵S and IL-1 β specific proteins were immunoprecipitated from cell lysates. The immunoprecipitates were analyzed by SDS-PAGE and autoradiography. We found that transfected COS-7 cells can process precursor IL-1 β to mature IL-1 β only if the cells were co-transfected with a plasmid encoding IL-1 β pro. Cells co-transfected with a control plasmid or cells mock transfected did not show any processing of precursor IL-1 β . Thus, IL-1 β pro, lacking

the N-terminal 119 amino acids enables cells to process precursor IL-1 β to the mature form of this protein.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: BLACK, ROY A
SLEATH, PAUL R
KRONHEIM, SHIRLEY R
- (ii) TITLE OF INVENTION: INTERLEUKIN 1B PROTEASE AND INTERLEUKIN
1B PROTEASE INHIBITORS
- (iii) NUMBER OF SEQUENCES: 24
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: DRESSLER, GOLDSMITH, SHORE, SUTKER & MILNAMOW
 - (B) STREET: 180 N. STETSON
 - (C) CITY: CHICAGO
 - (D) STATE: IL
 - (E) COUNTRY: USA
 - (F) ZIP: 60601
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.24
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: KATZ, MARTIN L.
 - (B) REGISTRATION NUMBER: 25011
 - (C) REFERENCE/DOCKET NUMBER: IMMUNEX2108
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 3126165400
 - (B) TELEFAX: 3126165460
 - (C) TELEX: 9102211206

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1659 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAAAGGAGAG	AAAAGCCTAA	AAGAGAGTGG	GTAGATGGCC	GACAAGGTCC	TGAAGGAGAA	60
GAGAAAGCTG	TTTATCCGTT	CCATGGGTGA	AGGTACAATA	AATGGCTTAA	GGTAGAAGGT	120
GAAGGAAATA	CTGGATGAAT	TATTACAGAC	AAGGGTGCTG	AACAAGGAAG	AGATGGAGAA	180
AGTAAAACGT	GAAAATGCTA	CAGTTTATAG	AAAAGAAGAA	CGCTTATGGA	TAAGACCCGA	240
GCTTTGATTG	ACTCCGTTAT	TCCGAAAGGG	GCACAGGCAT	GCCAAATTG	CATCACATAC	300
CGGATAAGTG	AAAGTGATAA	TTTGTGAAGA	AGACAGTTAC	CTGGCAGGGA	CGCTGGGACT	360
CTCAGCAGAT	CAAACATCTG	GAAATTACCT	TAATTGAGGA	AAGAAAGAAA	ATTATGCAAG	420
ACTCTCAAGG	AGTACTTTCT	TCCTTTCCAG	CTCCTCAGGC	AGTGCAGGAC	AACCCAGCTA	480
TGCCCCACAGG	GAACGGAAGA	GTGAATCCTC	AGGCTCAGAA	GGGAATGTCA	AGCTTTGCTC	540
CCTAGAAGAA	GCTCAAAGGA	TATGGAAACA	AAAGTCGGCA	GTTAAGTAGA	ACAGGAGAGA	600
TTTATCCAAT	AATGGACAAG	TCAAGCCGCA	CACGTCTTGC	TCTCATTATC	TGCAATGAAG	660
AATTTGACAG	TAGAGTGAAG	AATGTTTGAG	TAATTCCTAG	AAGAACTGGA	GCTGAGGTTG	720
ACATCACAGG	CATGACAATG	CTGCTACAAA	ATCTGGGGTA	CAGCGTAAAA	TAAATTTGGA	780
AAAAGGGATG	TGAAAAAAAA	TCTCACTGCT	TCGGACATGA	CTACAGAGCT	GGAGGCATTT	840
GCACACCGCC	CAGAGCACAA	GTATATGAGG	GCGGACCTCT	GACAGCACGT	TCCTGGTGTT	900
CATGTCTCAT	GGTATTCGGG	AAGGCATTTG	TGGGAAGAAA	CACTCTGAGG	AAGAAAATAT	960
ACACAAGTCC	CAGATATACT	ACAACTCAAT	GCAATCTTTA	ACATGTTGAA	TACCAAGAAC	1020
TGCCCAAGTT	TGAAGGACAG	AACAGGAGAA	TAAGAAACCG	AAGGTGATCA	TCATCCAGGC	1080
CTGCCGTGGT	GACAGCCCTG	GTGTGGTGTG	GTTTAAAGAT	TCAGTAGGAA	GATTGGGAAA	1140
AAAGGTTTCT	GGAAACCTAT	CTTTACCAAC	TACAGAAGAG	TTTGAGGATG	ATGCTATTAA	1200
GAAAGCCCAC	ATAGAGAAGA	AACTAAATAG	TTGAGATTTT	ATCGCTTTCT	GCTCTTCCAC	1260
ACCAGATAAT	GTTTCTTGGA	GACATCCCAC	AATGGGCTCT	GTTTTTATTG	AGGTGGTAAC	1320
CAAGGAGAAG	GGAAGACTCA	TTGAACATAT	GCAAGAATAT	GCCTGTTCCCT	GTGATGTGGA	1380
GGAAATTTTC	CGCAAGGTTC	GATTTGGAGA	GAAGTTTGAG	ATTAGCTTCA	TTTGAGCAGC	1440
CAGATGGTAG	AGCGCAGATG	CCCACCACTG	AAAGAGTGAC	TTTGACAAGA	TGTTTCTACC	1500

TCGTTCCCAG GACATTAAAA TAAGGAACT GTATGAATGT CTGCGGGCAG GAAGTGAAGA 1560
 GATCGTTCTG TAAAAGGTTT TTGAATTAT GTCTGCTGAA TAATAAACTT TTTTGAAAT 1620
 AATAAATCTG GTAGAAAAAT GAAAAAAAAA AAAAAAAAAA 1659

(2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 404 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met	Ala	Asp	Lys	Val	Leu	Lys	Glu	Lys	Arg	Lys	Leu	Phe	Ile	Arg	Ser	1	5	10	15
Met	Gly	Glu	Gly	Thr	Ile	Asn	Gly	Leu	Leu	Asp	Glu	Leu	Leu	Gln	Thr	20	25	30	
Arg	Val	Leu	Asn	Lys	Glu	Glu	Met	Glu	Lys	Val	Lys	Arg	Glu	Asn	Ala	35	40	45	
Thr	Val	Met	Asp	Lys	Thr	Arg	Ala	Leu	Ile	Asp	Ser	Val	Ile	Pro	Lys	50	55	60	
Gly	Ala	Gln	Ala	Cys	Gln	Ile	Cys	Ile	Thr	Tyr	Ile	Cys	Glu	Glu	Asp	65	70	75	80
Ser	Tyr	Leu	Ala	Gly	Thr	Leu	Gly	Leu	Ser	Ala	Asp	Gln	Thr	Ser	Gly	85	90	95	
Asn	Tyr	Leu	Asn	Met	Gln	Asp	Ser	Gln	Gly	Val	Leu	Ser	Ser	Phe	Pro	100	105	110	
Ala	Pro	Gln	Ala	Val	Gln	Asp	Asn	Pro	Ala	Met	Pro	Thr	Ser	Ser	Gly	115	120	125	
Ser	Glu	Gly	Asn	Val	Lys	Leu	Cys	Ser	Leu	Glu	Glu	Ala	Gln	Arg	Ile	130	135	140	
Trp	Lys	Gln	Lys	Ser	Ala	Glu	Ile	Tyr	Pro	Ile	Met	Asp	Lys	Ser	Ser	145	150	155	160
Arg	Thr	Arg	Leu	Ala	Leu	Ile	Ile	Cys	Asn	Glu	Glu	Phe	Asp	Ser	Ile	165	170	175	

Pro Arg Arg Thr Gly Ala Glu Val Asp Ile Thr Gly Met Thr Met Leu
180 185 190

Leu Gln Asn Leu Gly Tyr Ser Val Asp Val Lys Lys Asn Leu Thr Ala
195 200 205

Ser Asp Met Thr Thr Glu Leu Glu Ala Phe Ala His Arg Pro Glu His
210 215 220

Lys Thr Ser Asp Ser Thr Phe Leu Val Phe Met Ser His Gly Ile Arg
225 230 235 240

Glu Gly Ile Cys Gly Lys Lys His Ser Glu Gln Val Pro Asp Ile Leu
245 250 255

Gln Leu Asn Ala Ile Phe Asn Met Leu Asn Thr Lys Asn Cys Pro Ser
260 265 270

Leu Lys Asp Lys Pro Lys Val Ile Ile Ile Gln Ala Cys Arg Gly Asp
275 280 285

Ser Pro Gly Val Val Trp Phe Lys Asp Ser Val Gly Val Ser Gly Asn
290 295 300

Leu Ser Leu Pro Thr Thr Glu Glu Phe Glu Asp Asp Ala Ile Lys Lys
305 310 315 320

Ala His Ile Glu Lys Asp Phe Ile Ala Phe Cys Ser Ser Thr Pro Asp
325 330 335

Asn Val Ser Trp Arg His Pro Thr Met Gly Ser Val Phe Ile Gly Arg
340 345 350

Leu Ile Glu His Met Gln Glu Tyr Ala Cys Ser Cys Asp Val Glu Glu
355 360 365

Ile Phe Arg Lys Val Arg Phe Ser Phe Glu Gln Pro Asp Gly Arg Ala
370 375 380

Gln Met Pro Thr Thr Glu Arg Val Thr Leu Thr Arg Cys Phe Tyr Leu
385 390 395 400

Phe Pro Gly His

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 269 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Met	Ala	Glu	Val	Pro	Glu	Leu	Ala	Ser	Glu	Met	Met	Ala	Tyr	Tyr	Ser			
1				5					10					15				
Gly	Asn	Glu	Asp	Asp	Leu	Phe	Phe	Glu	Ala	Asp	Gly	Pro	Lys	Gln	Met			
			20					25					30					
Lys	Cys	Ser	Phe	Gln	Asp	Leu	Asp	Leu	Cys	Pro	Leu	Asp	Gly	Gly	Ile			
		35					40					45						
Gln	Leu	Arg	Ile	Ser	Asp	His	His	Tyr	Ser	Lys	Gly	Phe	Arg	Gln	Ala			
	50					55					60							
Ala	Ser	Val	Val	Val	Ala	Met	Asp	Lys	Leu	Arg	Lys	Met	Leu	Val	Pro			
65					70					75					80			
Cys	Pro	Gln	Thr	Phe	Gln	Glu	Asn	Asp	Leu	Ser	Thr	Phe	Phe	Pro	Phe			
				85					90					95				
Ile	Phe	Glu	Glu	Glu	Pro	Ile	Phe	Phe	Asp	Thr	Trp	Asp	Asn	Glu	Ala			
			100					105					110					
Tyr	Val	His	Asp	Ala	Pro	Val	Arg	Ser	Leu	Asn	Cys	Thr	Leu	Arg	Asp			
		115					120					125						
Ser	Gln	Gln	Lys	Ser	Leu	Val	Met	Ser	Gly	Pro	Tyr	Glu	Leu	Lys	Ala			
	130					135					140							
Leu	His	Leu	Gln	Gly	Gln	Asp	Met	Glu	Gln	Gln	Val	Val	Phe	Ser	Met			
145					150				155						160			
Ser	Phe	Val	Gln	Gly	Glu	Glu	Ser	Asn	Asp	Lys	Ile	Pro	Val	Ala	Leu			
				165					170					175				
Gly	Leu	Lys	Glu	Lys	Asn	Leu	Tyr	Leu	Ser	Cys	Val	Leu	Lys	Asp	Asp			
			180					185					190					
Lys	Pro	Thr	Leu	Gln	Leu	Glu	Ser	Val	Asp	Pro	Lys	Asn	Tyr	Pro	Lys			
		195					200					205						
Lys	Lys	Met	Glu	Lys	Arg	Phe	Val	Phe	Asn	Lys	Ile	Glu	Ile	Asn	Asn			
	210					215					220							
Lys	Leu	Glu	Phe	Glu	Ser	Ala	Gln	Phe	Pro	Asn	Trp	Tyr	Ile	Ser	Thr			
225					230					235					240			
Ser	Gln	Ala	Glu	Asn	Met	Pro	Val	Phe	Leu	Gly	Gly	Thr	Lys	Gly	Gly			
				245					250					255				

Gln Asp Ile Thr Asp Phe Thr Met Gln Phe Val Ser Ser
260 265

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TACCGGCTGT TCCAGGAC 18

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TACCTATTCT GGGCTCGA 18

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

TTGGTCGATA CGGGTGT 17

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CACCACACCA AATTCTA 18

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

ATGGAGAAGG GTCCTGTA 18

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GTCGAATTCA AYCCNGCNAT GCCNAC 26

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GTCTCTAGAA GYTTNACRTT NCCYTC 26

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

ATATCGGTAC CGCCTCCAGC ATGCCTCCGG CAATGCCCCAC ATC 43

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

CTGCTAGATC TGCCCGCAGA CATTCATACA G 31

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Ala Tyr Val His Asp Ala Pro Val Arg Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Ala	Tyr	Val	His	Asn	Ala	Pro	Val	Arg	Ser
1				5					10

(2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Ala	Tyr	Val	His	Glu	Ala	Pro	Val	Arg	Ser
1				5					10

(2) INFORMATION FOR SEQ ID NO: 16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (ix) FEATURE:
 - (B) LOCATION: 4
 - (C) IDENTIFICATION METHOD: Xaa = D-Asp
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Ala	Tyr	Val	His	Xaa	Ala	Pro	Val	Arg	Ser
1				5					10

(2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10 amino acids
 - (B) TYPE: amino acid

(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Ala	Tyr	Val	His	Asp	Gly	Pro	Val	Arg	Ser
1				5					10

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Ala	Tyr	Val	His	Asp	Val	Pro	Val	Arg	Ser
1				5					10

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

Ala	Tyr	Val	Phe	Asp	Ala	Pro	Val	Arg	Ser
1				5					10

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Ala	Tyr	Val	His	Asp	Ala	Ala	Val	Arg	Ser
1				5					10

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 12 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Glu Ala Tyr Val His Asp Ala Pro Val Arg Ser Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO: 22:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Tyr Val His Asp Ala Pro Val Arg
1 5

(2) INFORMATION FOR SEQ ID NO: 23:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: peptide
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

Val His Asp Ala Pro Val
1 5

(2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 4 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

His Asp Ala Pro

1

WHAT IS CLAIMED IS:

1. An isolated polypeptide having protease activity for a specific protease cleavage site, wherein the protease activity is specific for a substrate peptide having an amino acid sequence comprising:



wherein R_1 and R_3 are independently any D or L isomer amino acid, R_2 is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R_2 .

2. The isolated polypeptide of claim 1 wherein the substrate peptide is at least eight amino acids in length.

3. An isolated IL-1 β pro polypeptide having IL-1 β pro activity and encoded by a DNA sequence comprising:

a. a DNA insert selected from the group consisting of the nucleotide sequences in Seq. I.D. No. 1 beginning at nucleotide 1 and extending to nucleotide 1232, beginning at nucleotide 374 and extending to nucleotide 1232, and beginning at nucleotide 374 and extending to a nucleotide from about 851 to about 962,

b. DNA sequences which detectably hybridize to one or more of the foregoing DNA inserts and which code or express a polypeptide displaying biological activity to proteolytically cleave human precursor IL-1 β polypeptide at a cleavage site between the Asp 116 and Ala 117 residues; and

c. DNA sequences which, due to degeneracy of the genetic code, encode a mammalian IL-1 β pro polypeptide encoded by any of the foregoing DNA inserts and sequences.

4. The isolated polypeptide of claim 3 wherein the protein sequence is selected from the group consisting of amino acid 1 to amino acid 404, amino acid 51 to amino acid 404, amino acid 120 to an amino acid beginning at position 278 and extending to amino acid 315, and amino acid 120 to amino acid 404 of Seq. I.D. No. 2.

5. An isolated DNA sequence encoding a mammalian IL-1 β pro enzyme.

6. The isolated DNA sequence of claim 5 wherein the mammalian IL-1 β pro enzyme is a human IL-1 β pro enzyme.

7. The isolated DNA sequence of claim 5 wherein the DNA sequence comprises:

a. a DNA insert selected from the group consisting of the nucleotide sequences in Seq. I.D. No. 1 beginning at nucleotide 1 and extending to nucleotide 1232, beginning at nucleotide 374 and extending to nucleotide 1232, beginning at nucleotide 374 and extending to a nucleotide from about 851 to about 962;

b. DNA sequences which detectably hybridize to one or more of the foregoing DNA inserts and which code or express a polypeptide displaying biological activity to proteolytically cleave human precursor IL-1 β polypeptide at a cleavage site between the Asp 116 and Ala 117 residues; and

c. DNA sequences which, due to degeneracy of the genetic code, encode a mammalian IL-1 β pro polypeptide encoded by any of the foregoing DNA inserts and sequences.

8. A recombinant expression vector comprising a DNA sequence according to claim 5.

9. A recombinant expression vector comprising a DNA sequence according to claim 6.

10. A recombinant expression vector comprising a DNA sequence according to claim 7.

11. A process for preparing a mammalian IL-1 β pro enzyme or an analog or derivative thereof, comprising culturing a suitable host cell comprising a vector according to claim 8 under conditions promoting expression.

12. A process for preparing a mammalian IL-1 β pro enzyme or an analog or derivative thereof, comprising culturing a suitable host cell comprising a vector according to claim 9 under conditions promoting expression.

13. A process for preparing a mammalian IL-1 β pro enzyme or an analog or derivative thereof, comprising culturing a suitable host cell comprising a vector according to claim 10 under conditions promoting expression.

14. A method for improving wound healing at a wound site comprising administering a pharmaceutical composition to the wound site comprising the isolated polypeptide of claim 1 in a suitable pharmaceutical carrier.

15. A method for treating arthritis comprising administering a pharmaceutical composition

comprising the isolated polypeptide of claim 1 in a suitable pharmaceutical carrier.

16. A method for treating an autoimmune disease in a susceptible individual comprising administering a pharmaceutical composition comprising the isolated polypeptide of claim 1 in a suitable pharmaceutical carrier.


17. The method of claim 16 wherein the autoimmune disease is selected from the group consisting of Insulin-dependent diabetes melitus, Graves' disease, Hashimotos disease and a lupus disease.

18. A method for reducing the detrimental side effects of radiation treatment comprising administering a pharmaceutical composition comprising the isolated polypeptide of claim 1 in a suitable pharmaceutical carrier.

19. An antisense oligonucleotide comprising a sequence of at least 15 nucleotides complementary to a sequence of IL-1 β pro cDNA, wherein said antisense oligonucleotide inhibits translation of IL-1 β pro mRNA.

20. A compound comprising an amino acid sequence of from 1 to about 5 amino acid residues having an N-terminal blocking group and a C-terminal Asp residue connected to an electronegative leaving group, wherein said amino acid sequence substantially corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3.

21. The compound according to claim 20 having the formula:



where Z is an N-terminal protecting group;

Q_2 is 0 to 4 amino acids such that the sequence Q_2 -Asp substantially corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3; and

Q_1 is an electronegative leaving group:

22. The compound according to claim 21 wherein Z is C_1 - C_6 alkyl, benzyl, acetyl, C_1 - C_6 alkoxy carbonyl, benzyloxy carbonyl or C_1 - C_6 alkyl carbonyl.

23. The compound according to claim 21 wherein Z is t-butoxy carbonyl, acetyl or benzyloxy carbonyl.


24. The compound according to claim 21 wherein Q_1 is an aldehyde, a diazomethyl ketone or a halomethyl ketone.

25. The compound according to claim 21 wherein Q_1 is fluoromethyl ketone.

26. The compound according to claim 21 wherein Q_2 is 1 amino acid residue.

27. The compound according to claim 21 wherein Q_2 is His, Phe, Pro or Tyr.

28. A pharmaceutical composition comprising a physiologically acceptable carrier and a compound of the formula:



where Z is an N-terminal protecting group;

Q_2 is 0 to 4 amino acids such that Q_2 -Asp substantially corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3; and
 Q_1 is an electronegative leaving group:

29. The composition according to claim 28 wherein Z is C_1 - C_6 alkyl, benzyl, acetyl, C_1 - C_6 alkoxy carbonyl, benzyloxy carbonyl or C_1 - C_6 alkoxy carbonyl, benzyloxy carbonyl or C_1 - C_6 alkyl carbonyl.

30. The composition according to claim 28 wherein Z is t-butoxy carbonyl, acetyl or benzyloxy carbonyl.

31. The composition according to claim 28 wherein Q_1 is an aldehyde, a diazomethyl ketone or a halomethyl ketone.

32. The composition according to claim 28 wherein Q_1 is fluoromethyl ketone.

33. The composition according to claim 28 wherein Q_2 is 1 amino acid residue.

34. The composition according to claim 28 wherein Q_2 is His, Phe, Pro or Tyr.

35. A method of inhibiting IL-1 β protease activity in a mammal in need of such treatment comprising administering to said mammal an effective inhibitory amount of a compound of the formula:



where Z is an N-terminal protecting group;

Q_2 is 0 to 4 amino acids such that the sequence Q_2 -Asp substantially corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3; and

Q_1 is an electronegative leaving group.

36. The method according to claim 35 wherein Z is C_1 - C_6 alkyl, benzyl, acetyl, C_1 - C_6 alkoxy carbonyl, benzyloxy carbonyl or C_1 - C_6 alkyl carbonyl.

37. The method according to claim 35 wherein Z is t-butoxy carbonyl, acetyl or benzyloxy carbonyl.

38. The method according to claim 35 wherein Q_1 is an aldehyde, a diazomethyl ketone or a halomethyl ketone.

39. The method according to claim 35 wherein Q_2 is 1 amino acid residue.

40. The method according to claim 35 wherein Q_2 is His, Phe, Pro or Tyr.

41. The method according to claim 35 wherein Q_1 is an aldehyde and inhibiting is reversibly inhibiting.

42. The method according to claim 35 wherein Q_1 is fluoromethyl ketone and inhibiting is irreversibly inhibiting.

43. A method of treating inflammation or preventing and treating an autoimmune disease in a mammal in need of such treatment comprising administering to said mammal an effective amount of a compound of the formula:

Z-Q₂-Asp-Q₁

where Z is an N-terminal protecting group;

Q₂ is 0 to 4 amino acids such that the sequence Q₂-Asp substantially corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp, residues 112 to 116 of Seq. I.D. No. 3; and

Q₁ is an electronegative leaving group:

44. The method according to claim 43 wherein Z is C₁-C₆ alkyl, benzyl, acetyl, C₁-C₆ alkyl carbonyl.

45. The method according to claim 43 wherein Z is t-butoxycarbonyl, acetyl or benzyloxycarbonyl.

46. The method according to claim 43 wherein Q₁ is an aldehyde, a diazomethyl ketone or a halomethyl ketone.


47. The method according to claim 43 wherein Q₂ is 1 amino acid residue.

48. The method according to claim 43 wherein Q₂ is His, Phe, Pro or Tyr.

49. A compound selected from the group consisting of Boc-Asp-CF₂F, Boc-His-Asp-CH₂F, Boc-Phe-Asp-CH₂F, Boc-Pro-Asp-CH₂F, Boc-Tyr-Asp-CH₂F, Ac-His-Asp-CH₂F, Ac-Phe-Asp-CH₂F, Ac-Pro-Asp-CH₂F, Ac-Tyr-Asp-CH₂F, Cb₃-His-Asp-CH₂F, Cb₃-Phe-Asp-CH₂F, Cb₃-Pro-Asp-CH₂F, and Cb₃-Tyr-Asp-CH₂F wherein Boc is t-butoxycarbonyl, Ac is acetyl and Cb₃ is benzyloxycarbonyl.

ABSTRACT OF THE DISCLOSURE

There is disclosed an isolated polypeptide and derivatives thereof having protease biological activity for human precursor IL-1 β and for a substrate comprising:



wherein R_1 and R_3 are independently any D or L isomer amino acid, R_2 is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R_2 . Inhibitor compounds, compositions and methods for inhibiting Interleukin 1 β protease activity are also disclosed. The inhibitor compounds comprise an amino acid sequence of from 1 to about 5 amino acids having an N-terminal blocking group and a C-terminal Asp residue connected to an electronegative leaving group, wherein the amino acid sequence corresponds to the sequence Ala-Tyr-Val-His-Asp.

FIG. 1A

5'-AAAAAGGAGAGAAAAGCC	17
Met Ala Asp Lys Val Leu Lys Glu Lys Arg Ser Met Gly Glu Gly Thr Ile Asn Gly Leu	25
ATG GCC GAC AAG GTC CTG AAG GAG AAG AGA AAG CTG TTT ATC CGT TCC ATG GGT GAA GGT ACA ATA AAT GGC TTA	92
Leu Asp Glu Leu Leu Gln Thr Arg Val Leu Asn Lys Glu Met Glu Lys Val Lys Arg Glu Asn Ala Thr Val	50
CTG GAT GAA TTA TTA CAG ACA AGG GTG CTG AAC AAG GAA GAG ATG GAG AAA GTA AAA CGT GAA AAT GCT ACA GTT	167
Met Asp Lys Thr Arg Ala Leu Ile Asp Ser Val Ile Pro Lys Gly Ala Gln Ala Cys Gln Ile Cys Ile Thr Tyr	75
ATG GAT AAG ACC CGA GCT TTG ATT GAC TCC GGT ATT CCG AAA GGG GCA CAG GCA TGC CAA ATT TGC ATC ACA TAC	242
Ile Cys Glu Glu Asp Ser Tyr Leu Ala Gly Thr Leu Gly Leu Ser Ala Asp Gln Thr Ser Gly Asn Tyr Leu Asn	100
ATT TGT GAA GAA GAC AGT TAC CTG GCA GGG ACG CTG GGA CTC TCA GCA GAT CAA ACA TCT GGA AAT TAC CTT AAT	317
Met Gln Asp Ser Gln Gly Val Leu Ser Phe Pro Ala Pro Gln Ala Val Gln Asp Asn Pro Ala Met Pro Thr	125
ATG CAA GAC TCT CAA GGA GTA CTT TCT TCC TCC TTT CCA GCT CCT CAG GCA GTG CAG GAC AAC CCA GCT ATG CCC ACA	392
Ser Ser Gly Ser Glu Gly Asn Val Lys Leu Cys Ser Leu Glu Ala Gln Arg Ile Trp Lys Gln Lys Ser Ala	150
TCC TCA GGC TCA GAA GGG AAT GTC AAG CTT TGC TCC TCA GAA GAA GCT CAA AGG ATA TGG AAA CAA AAG TCG GCA	467
Glu Ile Tyr Pro Ile Met Asp Lys Ser Arg Thr Arg Leu Ala Leu Ile Cys Asn Glu Glu Phe Asp Ser	175
GAG ATT TAT CCA ATA ATG GAC AAG TCA AGC CGC ACA CGT CTT GCT CTC ATT ATC TGC AAT GAA GAA TTT GAC AGT	542
Ile Pro Arg Arg Thr Gly Ala Glu Val Asp Ile Thr Gly Met Thr Met Leu Leu Gln Asn Leu Gly Tyr Ser Val	200
ATT CCT AGA AGA ACT GGA GCT GAG GTT GAC ATC ACA GGC ATG ACA ATG CTG CTA CAA AAT CTG GGG TAC AGC GTA	617
Asp Val Lys Lys Asn Leu Thr Ala Ser Asp Met Thr Thr Glu Leu Glu Ala Phe Ala His Arg Pro Glu His Lys	225
GAT GTG AAA AAA AAT CTC ACT GCT TCG GAC ATG ACT ACA GAG CTG GAG GCA TTT GCA CAC CGC CCA GAG CAC AAG	692
Thr Ser Asp Ser Thr Phe Leu Val Phe Met Ser His Gly Ile Arg Glu Gly Ile Cys Gly Lys Lys His Ser Glu	250
ACC TCT GAC AGC ACG TTC CTG GTG TTC ATG TCT CAT GGT ATT CGG GAA GGC ATT TGT GGG AAG AAA CAC TCT GAG	767

FIG. 1B


Gln Val Pro Asp Ile Leu Gln Leu Asn Ala Ile Phe Asn Met Leu Asn Thr Lys Asn Cys Pro Ser Leu Lys Asp	275
CAA GTC CCA GAT ATA CTA CAA CTC AAT GCA ATC TTT AAC ATG TTG AAT ACC AAG AAC TGC CCA AGT TTG AAG GAC	842
Lys Pro Lys Val Ile Ile Gln Ala Cys Arg Gly Asp Ser Pro Gly Val Val Trp Phe Lys Asp Ser Val Gly	300
AAA CCG AAG GTG ATC ATC ATC CAG GCC TGC CGT GGT GGT GAC AGC CCT GGT GTG GTG TTT AAA GAT TCA GTA GGA	917
Val Ser Gly Asn Leu Ser Leu Pro Thr Thr Glu Glu Phe Glu Asp Asp Ala Ile Lys Lys Ala His Ile Glu Lys	325
GTT TCT GGA AAC CTA TCT TTA CCA ACT ACA GAA GAG TTT GAG GAT GAT GCT ATT AAG AAA GCC CAC ATA GAG AAG	992
Asp Phe Ile Ala Phe Cys Ser Thr Thr Pro Asp Asn Val Ser Trp Arg His Pro Thr Met Gly Ser Val Phe Ile	350
GAT TTT ATC GCT TTC TGC TGT TCC TCC ACA CCA GAT AAT GTT TCT TGG AGA CAT CCC ACA ATG GGC TCT GTT TTT ATT	1067
Gly Arg Leu Ile Glu His Met Gln Glu Tyr Ala Cys Ser Cys Asp Val Glu Glu Ile Phe Arg Lys Val Arg Phe	375
GGA AGA CTC ATT GAA CAT ATG CAA GAA TAT GCC TGT TCC TGT GAT GTG GAG GAA ATT TTC CGC AAG GTT CGA TTT	1142
Ser Phe Glu Gln Pro Asp Gly Arg Ala Gln Met Pro Thr Thr Glu Arg Val Thr Leu Thr Arg Cys Phe Tyr Leu	400
TCA TTT GAG CAG CCA GAT GGT AGA GCG CAG ATG CCC ACC ACT GAA AGA GTG ACT TTG ACA AGA TGT TTC TAC CTC	1217
Phe Pro Gly His End	404
TTC CCA GGA CAT TAA AATAAGGAAACTGTATGAATGTCGCGGCAGGAAGTGAAGAGATCGTTCGTAAAAGGTTTTTGGAAATTAATGTCGCT	1311
GAAATAAATAACTTTTTTTTGAATAATAAATCTCGGTAGAAAAAATGAAAAAATAAAAAA-3'	1374

FIG 2

Met	Ala	Glu	Val	Pro	Glu	Leu	Ala	Ser	Glu	Met	Met	Ala	Tyr	Tyr	Ser	
Gly	Asn	Glu	Asp	Asp	Leu	Phe	Phe	Glu	Ala	Asp	Gyl	Pro	Lys	Gln	Met	
Lys	Cys	Ser	Phe	Gln	Asp	Leu	Asp	Leu	Cys	Pro	Leu	Asp	Gly	Gly	Ile	
Gln	Leu	Arg	Ile	Ser	Asp	His	His	Tyr	Ser	Lys	Gly	Phe	Arg	Gln	Ala	
Ala	Ser	Val	Val	Val	Ala	Met	Asp	Lys	Leu	Arg	Lys	Met	Leu	Val	Pro	
Cys	Pro	Gln	Thr	Phe	Gln	Glu	Asn	Asp	Leu	Ser	Thr	Phe	Phe	Pro	Phe	
Ile	Phe	Glu	Glu	Glu	Pro	Ile	Phe	Phe	Asp	Thr	Trp	Asp	Asn	Glu	Ala	
Tyr	Val	His	Asp	Ala	Pro	Val	Arg	Ser	Leu	Asn	Cys	Thr	Leu	Arg	Asp	
Ser	Gln	Gln	Lys	Ser	Leu	Val	Met	Ser	Gly	Pro	Tyr	Glu	Leu	Lys	Ala	
Leu	His	Leu	Gln	Gly	Gln	Asp	Met	Glu	Gln	Gln	Val	Val	Phe	Ser	Met	
Ser	Phe	Val	Gln	Gly	Glu	Glu	Ser	Asn	Asp	Lys	Ile	Pro	Val	Ala	Leu	
Gly	Leu	Lys	Glu	Lys	Asn	Leu	Tyr	Leu	Ser	Cys	Val	Leu	Lys	Asp	Asp	
Lys	Pro	Thr	Leu	Gln	Leu	Glu	Ser	Val	Asp	Pro	Lys	Asn	Tyr	Pro	Lys	
Lys	Lys	Met	Glu	Lys	Arg	Phe	Val	Phe	Asn	Lys	Ile	Glu	Ile	Asn	Asn	
Lys	Leu	Glu	Phe	Glu	Ser	Ala	Gln	Phe	Pro	Asn	Trp	Tyr	Ile	Ser	Thr	
Ser	Gln	Ala	Glu	Asn	Met	Pro	Val	Phe	Leu	Gly	Gly	Thr	Lys	Gly	Gly	
Gln	Asp	Ile	Thr	Asp	Phe	Thr	Met	Gln	Phe	Val	Ser	Ser				

10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
220
230
240
250
260

FIG 3



DECLARATION AND POWER OF ATTORNEY

As the below-named inventors, we declare that we are the original, first, and sole inventors of the subject matter which is claimed in the specification identified below and for which a patent is sought on the invention as titled therein. We hereby state that we have reviewed and understand the contents of said specification including the claims. We acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 C.F.R. 1.56(a).

Inventor: SLEATH, Paul R.
Address: 836 West Armour Street
Seattle, WA 98119
Residence: Seattle, Washington, U.S.A.
Citizenship: U.K.

Inventor: BLACK, Roy A.
Address: 8062 30th Avenue N.E.
Seattle, WA 98115
Residence: Seattle, Washington, U.S.A.
Citizenship: U.S.A.

Inventor: KRONHEIM, Shirley R.
Address: 11526 36th Avenue N.E.
Seattle, WA 98125
Residence: Seattle, Washington, U.S.A.
Citizenship: Rep. of S.A.

Title of the Invention: **INTERLEUKIN-1 β PROTEASE AND
INTERLEUKIN-1 β PROTEASE INHIBITORS**

USSN: 750,644, filed on August 30, 1991

() There are no earlier-filed U. S. applications of which priority benefit is claimed.

(X) We hereby claim the benefit under 35 U.S.C. 120 of the United States application listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. 112, we acknowledge the duty to disclose material information as defined in 37 C.F.R. 156(a) which occurred between the filing date of the prior application and the filing date of this application:

USSN:	07/505,298	Filed:	April 4, 1990	Status:	Abandoned
	07/656,759		February 13, 1991		Abandoned

EI186820816US

POWER OF ATTORNEY

We hereby appoint the following as our attorneys or agents with full power of substitution to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

Imre Balogh, Reg. No. 26,835
William J. Davis, Reg. No. 30,744
Paul E. Dupont, Reg. No. 27,438
Michael D. Alexander, Reg. No. 36,080
Theodor C. Miller, Reg. No. 25,639
Irving Newman, Reg. No. 22,638
Arthur H. Rosenstein, Reg. No. 24,352
Frederick W. Stonner, Reg. No. 25,500

Please direct all future correspondence to:

Patent Department
Sterling Winthrop Inc.
81 Columbia Turnpike
Rensselaer, NY 12144

We further declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor:

Date Signed:

Paul R. Sleath
Paul R. Sleath

2/25/93


Roy A. Black
Roy A. Black

2/25/93

Shirley R. Kronheim
Shirley R. Kronheim

3/3/93

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



SCANNED, # 6

Application deficiencies were found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Scanned copy is best available.

There are only 4 sheets of drawing